1.
[
  {
    "Sl_no": 1,
    "Question": "Who is the author of this strategy execution plan?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 2,
    "Question": "What is the goal of this strategy, and what are its targets for
additional users in Nigeria by 2020?",
    "Question_Type": "Analytical"
  },
  {
    "Sl_no": 3,
    "Question": "What do you think will happen if the Bill & Melinda Gates Foundation
stops working with Oyo state?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 4,
    "Question": "What are some of the key points that BMGF is currently working across
in Nigeria and other high-potential countries to achieve its goal of 7 million
additional users by 2020?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 5,
    "Question": "What kind of political commitment is required for the NURHI project in
Nigeria?",
    "Question_Type": "Explanations"
  },
  {
    "Sl_no": 6,
    "Question": "How can some high-potential states be selected with the help of a Venn
diagram, and what are the criteria used to select BMGF demonstration states in this
case?",
    "Question_Type": "Analytical"
  },
  {
    "Sl_no": 7,
    "Question": "What would happen if Nigeria fulfills its FP2020 commitments by 2019
as stated in the infographic titled 'Scale tactic'?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 8,
    "Question": "What do you think will happen if the BMGF is not consistent and
proactive in all Nigeria messaging to maintain the high level call to action supporting
both the National FP Strategy and building PHC systems to achieve universal access?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 9,
    "Question": "What are some of the key strategies that BMGF is currently working
with in Nigeria?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 10,
    "Question": "How would you compare and contrast the roles of the FMOH and other
stakeholders in achieving the goal for additional users by 2020, as discussed under
'Stakeholder Alignment'?",
    "Question_Type": "Comparison"
  },
  {
    "Sl_no": 11,
    "Question": "What could be some of the reasons why Nigeria does not meet its goal
for the expected number of additional users in 2016 and beyond, according to the
infographic titled 'Key risks & issues'?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 12,
    "Question": "How could the BMGF be involved in addressing a high level risk for not
using contraception in Nigeria as discussed under 'Key Risks and Issues'?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 13,
    "Question": "What are some of the key reasons why donors may question the
commitment of the BMGF to its goal, according to the infographic titled 'Key risks &
issues'?",
    "Question_Type": "Explanations"
  },
  {
    "Sl_no": 14,
    "Question": "How could the NURHI project in Nigeria reach a high level of
confidence for addressing unmet needs as mentioned under the section 'Where we feel
confident'?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 15,
    "Question": "What are some key reasons why the NURHI project is likely to succeed,
according to the section 'Where we feel confident'?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 16,
    "Question": "How do you think some of the factors in the table of contents of this
strategy execution plan could be applied to real world problems?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 17,
    "Question": "What would happen if the NURHI project is not able to scale up in
Nigeria as stated in the 'Key Risks and Issues' infographic",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 18,
    "Question": "How do you compare and contrast the two sections 'What we have
concerns' and 'Where we feel confident' in the infographic titled 'Nigerian Urban
Reproductive Health Initiative'?",
    "Question_Type": "Comparison"
  },
  {
    "Sl_no": 19,
    "Question": "What are some reasons that could make some of the at-risk individuals
mentioned under 'Scale Tactic' not to use contraception, and what could be done about
it?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 20,
    "Question": "How do you think the BMGF could strengthen its strategy in Nigeria
with the help of a strategic evaluation chart for addressing national challenges as
shown under 'Strategy to Address Youth: Nigeria'?",
    "Question_Type": "Inference"
  }
]








2.[
  {
    "Sl_no": 1,
    "Question": "Why is it necessary for the World Health Assembly to track progress
for global nutrition targets in a country like India?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 2,
    "Question": "What was the main purpose of the Global Nutrition Report that was
published by IFPRI in 2014 and again in 2015, as stated in the context?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 3,
    "Question": "How many years did it take for the World Health Assembly to track
progress in the national context after they endorsed a set of global nutrition
targets?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 4,
    "Question": "What was the name given by the Global Nutrition Report to document
levels and trends in these targets for several countries, as stated in the context?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 5,
    "Question": "What were the two main goals of the National Family Health Surveys
(NHFS) based on health that have been conducted in India since 1992, as stated in the
context?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 6,
    "Question": "Who was responsible for performing a review of the surveys to see if
they were using the same measures as those globally, according to the context?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 7,
    "Question": "What is the purpose of the Global Nutrition Report, as stated in the
context?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 8,
    "Question": "How long did it take for a report from the survey to come out,
according to the context?",
    "Question_Type": "Factual",
    "Answer": "NA"
  },
  {
    "Sl_no": 9,
    "Question": "What type of surveys have been conducted in India by the National
Family Health Survey (NFHS) program for more than 9 years, as stated in the context?",
    "Question_Type": "Factual",
    "Answer": "NHFS"
  },
  {
    "Sl_no": 10,
    "Question": "Which of the six surveyed surveys have complete summary reports
available, as stated in the context?",
    "Question_Type": "Summary",
    "Answer": "NHS and RSCO"
  },
  {
    "Sl_no": 11,
    "Question": "For how many years has the annual Health Survey (AHS) been conducted
in India, according to the context?",
    "Question_Type": "Factual",
    "Answer": "< 1 year"
  },
  {
    "Sl_no": 12,
    "Question": "What is the name given to the report that was published by IFPRI in
2014 and again in 2015, as stated in the context?",
    "Question_Type": "Factual",
    "Answer": "Global Nutrition Report"
  },
  {
    "Sl_no": 13,
    "Question": "How many years is the average length of time between the NHFS and HDS,
according to the context?",
    "Question_Type": "Factual",
    "Answer": "4.5"
  },
  {
    "Sl_no": 14,
    "Question": "What is the name given by the World Health Assembly to a set of global
nutrition targets that must be tracked in the national context, as stated in the
context?",
    "Question_Type": "Summary",
    "Answer": "World Health Assembly global nutrition Targets"
  },
  {
    "Sl_no": 15,
    "Question": "Which two surveys have complete summary reports available for all of
their data sets and are in public domain, as stated in the context?",
    "Question_Type": "Factual",
    "Answer": "NHS and AHS CQB"
  },
  {
    "Sl_no": 16,
    "Question": "What is the name given by IFPRI to a set of global nutrition targets
that must be tracked in the national context, as stated in the context?",
    "Question_Type": "Summary",
    "Answer": "Global Nutrition Report"
  },
  {
    "Sl_no": 17,
    "Question": "What are the two main goals of the District Level Family Health
Surveys (DHLHS) that have been conducted by the National Sample Survey Organisation, as
stated in the context?",
    "Question_Type": "Factual",
    "Answer": "DLHHS"
  },
  {
    "Sl_no": 18,
    "Question": "What is the name given to a set of global nutrition targets that must
be tracked in the national context by the World Health Assembly, as stated in the
context?",
    "Question_Type": "Factual",
    "Answer": "World Health Assembly global nutrition Targets"
  },
  {
    "Sl_no": 19,
    "Question": "How long did it take for a report to come out from the Annual Health
Survey (AHS), as stated in the context?",
    "Question_Type": "Factual",
    "Answer": "< 1 year"
  },
  {
    "Sl_no": 20,
    "Question": "Which of the six surveyed surveys generated data at the district
level, as stated in the context?",
    "Question_Type": "Factual",
    "Answer": "The NHS and HUNGAMA"
  }
]




3.
[
        {
        "Sl_no":1,
        "Question":"How many global nutrition targets does the National Family Health Survey 
(NHFS) 3 and Rapid Survey on Children (RSCO) provide data on for the greatest number of
states?",
        "Question_Type":"Factual"
        },
        {
        "Sl_no":2,
        "What is the maximum time period between two rounds of the same survey in terms of ye
years, as per the context?",
        "Question_Type":"Factual"
        },
        {
        "Sl_no":3,
        "How many indicators are included in the National Family Health Survey (NHS) 4 compared
to the latest available round of the National Sample Survey Organisation (NSSO)?",
        "Question_Type":"Comparative"
        },
        {
        "Sl_no":4,
        "What is the maximum time gap between two rounds of the same survey, as per the conte
context?",
        "Question_Type":"Factual"
        },
        {
        "Sl_no":5,
        "How many surveys are included in this assessment to track the progress towards the g
global nutrition targets for children? Are all of them conducted by the same agency?",
        "Question_Type":"Comparative"
        },
        {
        "Sl_no":6,
        "What is the common reference age group used across most of the recent rounds of surv
surveys, as per the context?",
        "Question_Type":"Factual"
        },
        {
        "Sl_no":7,
        "Why does a single survey that consistently collects data for all six global nutrition
targets on a regular basis over time not exist in India?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":8,
        "What is the most comprehensive survey on nutrition available in the country, as per 
the context?",
        "Question_Type":"Factual"
        },
        {
        "Sl_no":9,
        "What is the minimum number of years required for the DHS to generate data at the dis
district level? What is the minimum time gap between two rounds of the same survey, as
per the context?",
        "Question_Type":"Comparative"
        },
        {
        "Sl_no":10,
        "How many nutrition targets have been adopted by the World Health Assembly and included
in the Global Nutrition Report 2014-2015 for India? What are those targets?",
        "Question_Type":"Factual"
        },
        {
        "Sl_no":11,
        "What is the main challenge faced in tracking the progress of a country's data on glo
global nutrition targets over time, as per the context?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":12,
        "What are some of the reasons why a single survey that consistently collects data for
all six global nutrition targets does not exist in India, as suggested by the research
team? What is the most comprehensive survey on nutrition available in the country, as
per the context?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":13,
        "What are some of the reasons why a single survey that consistently collects data for
all six global nutrition targets does not exist in India? How many surveys have been
conducted more than once, according to the research team? Which agency has conducted
these surveys?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":14,
        "How is the information regarding the geographical scope of the recent rounds of surv
surveys provided by the NHS 3 and HDS compared in the context?",
        "Question_Type":"Comparative"
        },
        {
        "Sl_no":15,
        "What are some of the challenges faced in tracking the progress of a country's data on
global nutrition targets over time? Why does a single survey that consistently collects
data for all six global nutrition targets not exist in India, as suggested by the
research team?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":16,
        "What is the reference group used to measure whether children under five years of age
have height-for-age z-scores < -2 standard deviations of the World Health
Organization's (WHO) child growth standards median, as per the context?",
        "Question_Type":"Factual"
        },
        {
        "What are some of the reasons why a single survey that consistently collects data for
all six global nutrition targets does not exist in India? What are the main challenges
faced in tracking the progress of a country's data on global nutrition targets over
time, as suggested by the research team?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":17,
        "Why did the National Family Health Survey 3 and HDS provide data on the greatest num
number of states, as per the context?",
        "Question_Type":"Factual"
        },
        {
        "What are some of the reasons why a single survey that consistently collects data for
all six global nutrition targets does not exist in India? What is the maximum time gap
between two rounds of the same survey, as per the context?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":18,
        "What are some of the challenges faced in tracking the progress of a country's data on
global nutrition targets over time? Why does a single survey that consistently collects
data for all six global nutrition targets not exist in India, as suggested by the
research team?",
        "Question_Type":"Inference"
        },
        {
        "Sl_no":19,
        "What is the purpose of the National Family Health Survey (NHS) 4 in terms of providing
data on the geographical scope of the surveys, as per the context?",
        "Question_Type":"Factual"
        },
        {
        "How does the availability of the complete data sets and the public domain documentat
documentation for a survey compared with other existing surveys, as suggested by the
research team? Which four of the targets included in the Global Nutrition Report
2014-2015 are included in the latest available round of the National Family Health
Survey (NHS), according to the context?",
        "Question_Type":"Comparative"
        },
        {
        "Sl_no":20,
        "Why did the National Family Health Survey (NHS) 3 and HDS provide data on the greatest
number of states, as per the context? What is the maximum time gap between two rounds
of the same survey, as per the context?",
        "Question_Type":"Inference"
        }
]


4.[
{
"Sl_no": "1",
"Question": "What is the main objective of the World Health Assembly of which India is
a member?",
"Question_Type": "Factual"
},
{
"Sl_no": "2",
"What set of nutrition outcomes have significant impact on short- and long-term human
development outcomes?",
"Question_Type": "Factual"
},
{
"Sl_no": "3",
"What are the six major nutrition surveys included in the assessment to track progress
towards global nutrition targets in India by the team from POSHAN?",
"Question_Type": "Factual"
},
{
"Sl_no": "4",
"How many years does it take for the NHS 2 and DHS 4 to generate data? Who generates
data for these two surveys?",
"Question_Type": "Analytical"
},
{
"Sl_no": "5",
"What are the major geographic criteria that the team from POSHAN assessed to determine
if a survey's estimates could be derived?",
"Question_Type": "Factual"
},
{
"Sl_no": "6",
"How many of the six surveys reviewed generated data at the district level? Which
surveys generated complete summary factsheets and datasets, and which ones did not
generate any report with documentation and data sets publicly available?",
"Question_Type": "Analytical"
},
{
"Sl_no": "7",
"What is the minimum number of years required to understand the current nutritional
status of India at the national and state levels based on a single survey? Which two
surveys provide the most recent data for the greatest number of states?",
"Question_Type": "Factual"
},
{
"Sl_no": "8",
"What are the four, five, and six targets that are included in the major surveys
reviewed by the team from POSHAN to track progress towards global nutrition targets?
Which survey provides a complete summary report for all indicators for the most recent
data?",
"Question_Type": "Summary"
},
{
"Sl_no": "9",
"Why is it important to understand the current nutritional status of India at the
national and state levels? What does this information tell us about the level of
development outcomes?",
"Question_Type": "Factual"
},
{
"Sl_no": "10",
"What are the six major surveys reviewed by the team from POSHAN to track progress
towards global nutrition targets in India?",
"Question_Type": "Summary"
},
{
"Sl_no": "11",
"Why is it necessary for the World Health Assembly to track its global nutrition
targets in the same manner across all countries? What does this require?",
"Question_Type": "Analytical"
},
{
"Sl_no": "12",
"What are the two surveys that have generated data at the district level among the six
reviewed by the team from POSHAN? Which one has generated a complete summary report for
all indicators for the most recent data and which one has not generated any report with
documentation and data sets publicly available?",
"Question_Type": "Analytical"
},
{
"Sl_no": "13",
"What is the average length of time between NHS and DHS, and 4.5 years for the HDS?
Which two surveys provide the most recent data among the six reviewed?",
"Question_Type": "Factual"
},
{
"Sl_no": "14",
"Why are some countries' progress in meeting the global nutrition targets over time not
easily determined? What is one reason given by the team from POSHAN to explain this
challenge?",
"Question_Type": "Summary"
},
{
"Sl_no": "15",
"What is a significant geographic challenge that is discussed as an obstacle for
comparing the existing data on levels and trends in nutrition, which the team from
POSHAN reviewed among six surveys?",
"Question_Type": "Factual"
},
{
"Sl_no": "16",
"What does the World Health Assembly do to track its global nutrition targets in all
countries? What are the six major surveys that were reviewed by the team from POSHAN to
understand why, if you could yield the required data, it is unclear why, and how this
information was documented?",
"Question_Type": "Summary"
},
{
"Sl_no": "17",
"What is the difference between the reference age group of the NHS 3 and that used by
some other surveys reviewed by the team from POSHAN for child anthropometry? What are
the five most recent surveys for which data has been generated on all six global
nutrition targets?",
"Question_Type": "Analytical"
},
{
"Sl_no": "18",
"How many years does it take to generate data between NHFS and HDS, and 4.5 years for
the DHS? Which two surveys have consistently collected data on nutrition in more than
nine years of their survey series?",
"Question_Type": "Factual"
},
{
"Sl_no": "19",
"What are the six major surveys reviewed by the team from POSHAN to track progress
towards global nutrition targets in India? What is one reason given for the challenge
of comparing the existing data on levels and trends in nutrition that the team from
POSHAN reviewed among these six surveys?",
"Question_Type": "Summary"
},
{
"Sl_no": "20",
"What are the two surveys that have a complete summary factsheet, and which survey has
only a summary factsheet or no report at all? What is one reason given by the team from
POSHAN to explain this difference in how data sets are publicly available?",
"Question_Type": "Analytical"
},
]


5.[{
"Sl_no": 1,
"Question": "What is the name of the technology that Samantha Budd Haerlein
represents?",
"Question_Type": "Factual"
},
{
"Sl_no": 2,
"Question": "Which disease does DCT's lead product apply to?",
"Question_Type": "Factual"
},
{
"Sl_no": 3,
"Question": "What is the primary focus of Rhoda Au's Framingham Heart Study since its
inception in 1948?",
"Question_Type": "Factual"
},
{
"Sl_no": 4,
"Question": "How many participants does the Framingham cohort consist of? What is their
age range?",
"Question_Type": "Factual"
},
{
"Sl_no": 5,
"Question": "What are the key challenges that Rhoda Au is facing with regards to data
sharing from her study?",
"Question_Type": "Analytical"
},
{
"Sl_no": 6,
"Question": "According to a 2016 Cochrane review, what is the sensitivity of the MMSE
for differentiating between neurodegenerative disorders like AD and vascular
dementia?",
"Question_Type": "Factual"
},
{
"Sl_no": 7,
"Question": "How does the accuracy of DCT's cognitive assessment test (clock drawing)
compare with that of MMSE in a validation study using a large patient dataset?",
"Question_Type": "Analytical"
},
{
"Sl_no": 8,
"Question": "What is the main innovation of Segerter's technology for EMR retrieval?",
"Question_Type": "Factual"
},
{
"Sl_no": 9,
"Question": "Why are some researchers resistant to sharing their data? What do funders
at NIA and NHBLI say about this?",
"Question_Type": "Analytical"
},
{
"Sl_no": 10,
"Question": "What is the main innovation of DCT's technology for the clock drawing test
that makes it a better screening tool than MMSE?",
"Question_Type": "Factual"
},
{
"Sl_no": 11,
"Question": "How can you use the digital pen technology to make the cognitive
assessment process more efficient and cost-effective?",
"Question_Type": "Application"
},
{
"Sl_no": 12,
"Question": "What kind of data do researchers face challenges with setting up in East
Asia, particularly when they want to recruit patients for studies or trials? How do you
see additional opportunities for external partnerships with academic studies and
patient groups evolving in the near future?",
"Question_Type": "Inference"
},
{
"Sl_no": 13,
"Question": "What are some of the challenges that Segerter's technology has to face
regarding access to EMR from different providers? Is there any plan to block the access
by those providers?",
"Question_Type": "Analytical"
},
{
"Sl_no": 14,
"Question": "How can Segerter's technology be used for identifying potential patients
for clinical trials or academic studies?",
"Question_Type": "Application"
},
{
"Sl_no": 15,
"Question": "Are there any plans to include other types of data besides those that you
are currently working on? How do you see additional opportunities for external
partnerships with academic studies and patient groups evolving in the near future?",
"Question_Type": "Inference"
},
{
"Sl_no": 16,
"Question": "What does DCT's lead product apply to?",
"Question_Type": "Factual"
},
{
"Sl_no": 17,
"Question": "Is there any plan to include additional sources of medical information
besides the ones you are currently working on? How do you see that technology evolving
in the near future?",
"Question_Type": "Inference"
},
{
"Sl_no": 18,
"Question": "What is the primary purpose of Samantha Budd Haerlein's
welcome/introduction segment of the session?",
"Question_Type": "Summary"
},
{
"Sl_no": 19,
"Question": "How can you use DCT's technology to improve your healthcare workforce? Do
you think the technology needs to be administered by a physician, or could a nurse or
PA do it?",
"Question_Type": "Application"
},
{
"Sl_no": 20,
"Question": "What is the name of Segerter's CEO and Co-Founder? What are some of the
key challenges that they have faced while developing their platform?",
"Question_Type": "Summary"
}
]

6.
[
{
"Sl_no": 1,
"Question": "What is the name of the company that aims to detect cognitive change
before overt symptoms?",
"Question_Type": "Factual"
},
{
"Sl_no": 2,
"What is the purpose of the Framingham Heart Study?",
"Question_Type": "Summary"
},
{
"Sl_no": 3,
"What is Segerter? What are its three main elements?",
"Question_Type": "Explanation"
},
{
"Sl_no": 4,
"What are some of the challenges in setting up cohort studies in East Asian
countries?",
"Question_Type": "Factual"
},
{
"Sl_no": 5,
"Why are some researchers resistant to sharing data from the Framingham Heart Study?
Who funds it at NIA and NHBLI?",
"Question_Type": "Inference"
},
{
"Sl_no": 6,
"What is the name of the study that aims to detect cognitive change before overt
symptoms using a digital pen?",
"Question_Type": "Factual"
},
{
"Sl_no": 7,
"What are the results of DCTClock in diagnosing dementia compared to MMSE?",
"Question_Type": "Analytical"
},
{
"Sl_no": 8,
"What are the differences between the Framingham Heart Study and other cohort
studies?",
"Question_Type": "Comparison"
},
{
"Sl_no": 9,
"How is Segerter's system used for sharing patient data? Does it require a subscription
or is it available to everyone?",
"Question_Type": "Inference"
},
{
"Sl_no": 10,
"What are the benefits and drawbacks of using DCTClock as an assessment tool in primary
care settings?",
"Question_Type": "Application"
},
{
"Sl_no": 11,
"How can Segerter's system be used to identify patients with a risk for, or who have
not yet been diagnosed with a disease? What are some ethical concerns involved with
this use of the technology?",
"Question_Type": "Inference"
},
{
"Sl_no": 12,
"What is the name of the other technology that uses digital pen to assess cognitive
impairment in people with neurodegenerative disorders such as Alzheimer's and
Parkinson's, including vascular dementia? What are its differentiators from traditional
tests for assessing these diseases?",
"Question_Type": "Factual"
},
{
"Sl_no": 13,
"Why do you think the field of Dementia is challenged in agreeing on one gold standard
cognitive test? How does this impact DCTClock and Segerter's work?",
"Question_Type": "Inference"
},
{
"Sl_no": 14,
"What are the similarities and differences between MMSE and DCTClock, and what were the
results for these tests when tested together in a large validation study?",
"Question_Type": "Comparison"
},
{
"Sl_no": 15,
"How does Segerter's system help to address the challenge of having too many different
sources of data that are not integrated with each other? Why would someone be
interested in using this service?",
"Question_Type": "Application"
},
{
"Sl_no": 16,
"What do you think is the most valuable information provided by the Framingham Heart
Study for Alzheimer's disease research? What does it have that other cohorts do not?",
"Question_Type": "Summary"
},
{
"Sl_no": 17,
"How would using Segerter's system impact the cost of sharing data from the Framingham
Heart Study? Is this a new business model in healthcare and how does it work?",
"Question_Type": "Inference"
},
{
"Sl_no": 18,
"What are some other sources of medical information that could be added to Segerter's
system for better patient data tracking, such as diet or sleep trackers?",
"Question_Type": "Application"
},
{
"Sl_no": 19,
"How is the use of technology by academic and industry studies like DCT and Segerter
likely to impact how these studies are funded in the future? Will this be a new
business model for Segerter and other companies that provide similar services?",
"Question_Type": "Inference"
},
{
"Sl_no": 20,
"What are some of the most valuable biomarkers or clinical trial outcome measures that
DCT has identified through their research, and what do they think would be good to
embed in future trials and studies? What is the potential for this information based on
the Framingham Heart Study?",
"Question_Type": "Inference"
},
]



7.[
    {
        "Sl_no": 1,
        "Question": "What was the aim of the Global Health (GH) private sector
engagement project?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 2,
        "Question": "Who were interviewed for the study on the GH private sector
strategy?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 3,
        "Question": "What are the three groups of opportunities mentioned in the
context? What is each opportunity category based on?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": 4,
        "Question": "Which five models were identified by the project for engaging the
private sector?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 5,
        "Question": "What does the term 'creative capitalism' refer to? How is this
term relevant in the context?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 6,
        "Question": "Explain the concept of 'creative capitalism'.",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 7,
        "Question": "How can BMGF adapt its operations and capabilities to take full
advantage of opportunities for engaging the private sector in pursuit of programmatic
needs?",
        "Question_Type": "Application"
    },
    {
        "Sl_no": 8,
        "Question": "What are some key external barriers that prevent private sector
participation in GH? What is the primary motivation behind this reluctance to
participate?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": 9,
        "Question": "What would be needed for BMGF's ability to pursue private sector
opportunities depending on the organizational capabilities within the Global Health
(GH) division? What does 'control' over PPP mean in the context?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": 10,
        "Question": "How will the engagement with the private sector be managed at the
most senior levels of BMGF leadership?",
        "Question_Type": "Application"
    },
    {
        "Sl_no": 11,
        "Question": "Explain how the 'brokering' model for engaging the private sector
is appropriate when there are several groups that can address the need in question. Is
this approach similar to the one used by GAIN?",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 12,
        "Question": "What would be needed from the human resources side for BMGF to
evolve towards a portfolio of different private sector engagement models?",
        "Question_Type": "Application"
    },
    {
        "Sl_no": 13,
        "Question": "Explain how the 'shaping the environment' model for engaging the
private sector can work. Why would this approach be less suitable for a push model like
the one used by GAVI and AMCs?",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 14,
        "Question": "What are some key external factors that might require more time,
effort, or investment to overcome when pursuing a 'shaping the environment' model?",
        "Question_Type": "Analysis"
    },
    {
        "Sl_no": 15,
        "Question": "Explain what would be required from the human resources side if
BMGF is willing to evolve towards using more of its organizational assets to engage
with the private sector in different ways. Why does this need not require a centralized
'first point of entry' for unsolicited opportunities?",
        "Question_Type": "Application"
    },
    {
        "Sl_no": 16,
        "Question": "How would BMGF's ability to control its agenda and influence
impact change, according to the context, when it takes a central role in shaping the
environment? Why might this require more time and investment?",
        "Question_Type": "Analysis"
    },
    {
        "Sl_no": 17,
        "Question": "What is the primary motivation behind the private sector's
reluctance to participate in solving GH problems? What are some common concerns voiced
by BMGF staff regarding a 'brokering' model for engaging with the private sector?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 18,
        "Question": "What does the 'first point of entry' mean in this context? What
would be required to create such a role at the BMGF level, and what kind of information
would be shared among the key account managers?",
        "Question_Type": "Application"
    },
    {
        "Sl_no": 19,
        "Question": "How does the 'shaping the environment' model for engaging with the
private sector compare to the push-push-intermediaries (e.g., PPPs)? Why is this
approach less well-established for the push-push model?",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 20,
        "Question": "What would be required from BMGF's human resources side if it is
willing to evolve towards using more of its organizational assets to engage with the
private sector in different ways? Why does this not require a centralized 'first point
of entry' for unsolicited opportunities?",
        "Question_Type": "Application"
    }
]



8.
[
    {
        "Sl_no": 1,
        "Question": "How has the lack of leadership within the management team been
observed by ACHAP's staff?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 2,
        "Question": "What are some significant changes that have taken place in the
proposed new organizational structure for ACHAP?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 3,
        "Question": "How does the new management team's responsibility for
implementation and development differ from the previous team? What is the nature of
this change?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": 4,
        "Question": "What are some implications that could have resulted from the
senior management team working in silos as described by ACHAP's staff?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 5,
        "Question": "How has the move to a new organizational structure been presented
to ACHAP's staff? Are there any significant changes that have taken place with this
structure?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 6,
        "Question": "What is the proposed role of the Director of Operations in the new
management team at ACHAP?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 7,
        "Question": "What are some ways that a lack of leadership by a senior
management team can impact an organization? Why is this so?",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 8,
        "Question": "How does ACHAP's current structure differ from the proposed new
structure, as discussed in the executive summary for all staff?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 9,
        "Question": "What is the proposed role of a Director of Program Development and
Implementation at ACHAP?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 10,
        "Question": "What are some advantages or disadvantages that could have resulted
from moving from a district focus to a regional one for government embedding in the new
management structure, as proposed in the executive summary for all staff?",
        "Question_Type": "Comparison"
    },
    {
        "Sl_no": 11,
        "Question": "How does ACHAP's current implementation and development functions
differ from the proposed new arrangement of having a separate director for each? What
are some benefits or drawbacks with this change?",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 12,
        "Question": "What is the main reason that ACHAP has an impressive individual
talent pool but lacks motivation among its staff, as observed by the staff
themselves?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 13,
        "Question": "How can ACHAP ensure a smooth transition to its new organizational
structure? What are some steps that could be taken to facilitate this process?",
        "Question_Type": "Application"
    },
    {
        "Sl_no": 14,
        "Question": "What is the main reason for the current lack of motivation among
ACHAP's staff, as observed by their staff?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 15,
        "Question": "What are some benefits that would result from having a clear and
separate relationship between seconded employees and ACHAP for the implementation
plan?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 16,
        "Question": "How do the Board and senior leadership need to act on the issues
of board structure and composition, as proposed in the recommendations to improve
Board-Organization Interactions, in order to address the above issues with ACHAP's
current management team?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 17,
        "Question": "What are some benefits that would result from the new structure
for a regional focus and an end to government embedding at ACHAP, as proposed in the
recommendations for building blocks of Phase 2?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 18,
        "Question": "How has the current management structure impacted ACHAP's staff
motivation level? What are some reasons that could be behind this lack of motivation,
as described in the recommendations to improve Board-Organization Interactions?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 19,
        "Question": "What are some implications for an organization if there is a
general lack of leadership at the senior level, like ACHAP has experienced? What is one
way that this could have affected its staff?",
        "Question_Type": "Explanation"
    },
    {
        "Sl_no": 20,
        "Question": "How can a regional focus with an end to government embedding
address some pressing short-term issues with the new management structure at ACHAP, as
described in the recommendations for building blocks of Phase 2? What are some possible
benefits from this change?",
        "Question_Type": "Summary"
    }
]



9.[
{
"Sl_no": "1",
"Question": "What is the historical focus of Bayer with regard to the contraceptive
market?",
"Question_Type": "Factual"
},

{
"Sl_no": "2",
"Question": "Which BCG team members were present in the interview with Tobias Ludwig on
January 18, 2019?",
"Question_Type": "Factual"
},

{
"Sl_no": "3",
"Question": "What is a key takeaway from the interview with Bayer's Portfolio and LCM
Manager, Tobias Ludwig, as told to Sarah Chamberlain of BCG and Christina Yu of BGC in
January 2019?",
"Question_Type": "Factual"
},

{
"Sl_no": "4",
"Question": "How does Bayer currently prioritize its market focus areas, particularly
with regard to women's needs and demands?",
"Question_Type": "Analytical"
},

{
"Sl_no": "5",
"Question": "What are the current main areas of focus in terms of R&D by BCG as told to
Tobias Ludwig in January 2019?",
"Question_Type": "Analytical"
},

{
"Sl_no": "6",
"Question": "According to Tobias Ludwig, what is the approach taken by Bayer when it
comes to the development and marketing of low-dose and non-hormonal options for birth
control?",
"Question_Type": "Explanation"
},

{
"Sl_no": "7",
"Question": "What is one of the key drivers that could change the demand and needs in
the women's health space according to Tobias Ludwig, BCG Portfolio Manager",
"Question_Type": "Explanation"
},

{
"Sl_no": "8",
"Question": "How do the values at Bayer influence its approach to the market with
regards to novel technological offerings?",
"Question_Type": "Comparison"
},

{
"Sl_no": "9",
"Question": "In which areas has BCG recently observed a change in women's needs and
demands according to Tobias Ludwig?",
"Question_Type": "Summary"
},

{
"Sl_no": "10",
"Question": "What is the current focus of R&D by BCG, as told by Tobias Ludwig, when it
comes to gynecological therapies, endometriosis, uterine fibroids, and the
contraceptive market?",
"Question_Type": "Summary"
},

{
"Sl_no": "11",
"Question": "Why did BCG decide to focus on developing its current product (USC) and
competitors in the first place?",
"Question_Type": "Explanation"
},

{
"Sl_no": "12",
"Question": "What is one of the main drivers for the changing landscape of women's
needs and demands as per the conversation with Tobias Ludwig?",
"Question_Type": "Factual"
},

{
"Sl_no": "13",
"Question": "According to Sarah Chamberlain, what was the approach taken by Bayer when
it comes to the development of its hormonal products in the past?",
"Question_Type": "Explanation"
},

{
"Sl_no": "14",
"Question": "How does BCG decide which projects or R&D activities to pursue according
to Tobias Ludwig?",
"Question_Type": "Application"
},

{
"Sl_no": "15",
"Question": "What is one of the approaches that BCG has taken as told by Christina Yu
with regards to the development and marketing of its current product (USC)?",
"Question_Type": "Application"
},

{
"Sl_no": "16",
"Question": "According to Tobias Ludwig, what are some of the key challenges BCG is
worried about when it comes to developing new products in the women's health space?",
"Question_Type": "Factual"
},

{
"Sl_no": "17",
"Question": "What does BCG consider as one of its current focus areas in the
development and R&D activities by Tobias Ludwig, January 2019?",
"Question_Type": "Summary"
},

{
"Sl_no": "18",
"Question": "Which company has been a significant partner for BMGF (Bill & Melinda
Gates Foundation) on projects related to the women's health space as per the
conversation with Tobias Ludwig in January 2019?",
"Question_Type": "Factual"
},

{
"Sl_no": "19",
"Question": "Why is BCG excited about hearing potential targets of interest from BMGF
according to the conversation with Tobias Ludwig in January 2019?",
"Question_Type": "Factual"
},

{
"Sl_no": "20",
"Question": "What could be a potential target of interest for BCG as per the
conversation with Tobias Ludwig in January 2019?",
"Question_Type": "Application"
}
]


10.[
        {
                "Sl_no": "1",
                "Question": "What is Bristol-Myers Squibb's current focus as it continues to develop a
more biopharmaceutical business?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "2",
                "Question": "What is the main factor behind the 9.8% increase in US sales from 2010-11,
as stated on the bar chart?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "3",
                "Question": "According to which geographical area does Bristol-Myers Squibb get most of
its revenue from?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "4",
                "Question": "Which region had the lowest percentage change in sales from 2010 to
2011?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "5",
                "Question": "What was the percentage change in Japan/Asia Pacific/Canada's sales from
2010-11, as stated on the bar chart?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "6",
                "Question": "What is the main driver of Bristol-Myers Squibb's new drug growth pipeline
according to its CEO Lambert Andreotti?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "7",
                "Question": "How has BMS' business strategy changed over the last five years, as stated
by CEO Lambert Andreotti?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "8",
                "Question": "What was the name of the company acquired for $2.5 billion to treat
hepatitis C in 2013?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "9",
                "Question": "Why does BMS not have an active strategy for emerging markets as a whole,
or any in-house mature products business, as stated in the context?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "10",
                "Question": "According to CEO Lambert Andreotti, which areas of R&D is Bristol-Myers
Squibb investing heavily in for future drug discovery and development?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "11",
                "Question": "What was the percentage increase in US sales from 2010 to 2011, according
to the bar chart?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "12",
                "Question": "According to what does CEO Lambert Andreotti call his strategy going
forward?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "13",
                "Question": "What are the main areas of focus for BMS' business development, as stated
in its strategic priorities going forward, according to the context?",
                "Question_Type": "Summary"
        },
        {
                "Sl_no": "14",
                "Question": "How does BMS expect China to rank among international drugmakers by
2014?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "15",
                "Question": "What was the percentage change in Latin America/ME/Africa's sales from
2010-11, according to the bar chart?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "16",
                "Question": "What are some of the ways that BMS is currently using partnerships to
increase its penetration in emerging markets, as stated in the context?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "17",
                "Question": "According to what type of diseases does BMS expect to invest heavily in
developing the next generation of cancer treatments, as stated by CEO Lambert
Andreotti?",
                "Question_Type": "Summary"
        },
        {
                "Sl_no": "18",
                "Question": "Why do you think a \"string of pearls\" strategy might be helpful for
Bristol-Myers Squibb in terms of business development, according to the context?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "19",
                "Question": "What is BMS' approach to emerging markets as a whole, as stated by its CEO
Lambert Andreotti, or for specific geographic areas such as Latin America/ME/Africa?",
                "Question_Type": "Inference"
        },
        {
                "Sl_no": "20",
                "Question": "What is the name of the company that Bristol-Myers Squibb acquired to
expand its diabetes franchise in 2012, according to the context?",
                "Question_Type": "Factual"
        }
]



11.
[
  {
    "Sl_no": 1,
    "Question": "What is one of the key reasons why Senegal's sanitation status is more
advanced than that in most developing countries?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 2,
    "Question": "How many autonomous organizations were created under the 'Primary
Objective' of the 'Water Sector Project' to increase the efficiency and enhance the
provision of water and sanitation services through public-private partnerships?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 3,
    "Question": "What was one of the key initiatives that was prolonged by the Long-
Term Water Supply Project (PLT)?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 4,
    "Question": "Which public enterprise is responsible for operating water services in
urban areas?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 5,
    "Question": "Which three key components are the primary objectives of the 'Long
Term Water Sector Project' (PLT)?",
    "Question_Type": "Analytical"
  },
  {
    "Sl_no": 6,
    "Question": "What was one of the main reasons why the government initiated a broad
range of reforms to revitalize progress in the water and sanitation sector?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 7,
    "Question": "How is the 'Regulation of the Water and Sanitization Sector' described
in terms of contracts and directories?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 8,
    "Question": "What is one of the primary objectives of the 'National Water Supply
and Sanitation Program for the Millennium'?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 9,
    "Question": "According to which year is the target for having 100% sanitation
coverage in urban areas, and 82% access to drinking water in rural areas?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 10,
    "Question": "What was one of the major challenges for Sanitation Program for
Peri-Urban Areas of Dakar (PAQPUD) as mentioned under 'Key Initiatives that Enhanced
Sanitation Facilities in Dakar'?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 11,
    "Question": "What is the name of the autonomous organization responsible for the
operation and management of sanitation services in urban and peri-urban areas?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 12,
    "Question": "According to which year was SONES dissolved into the National Water
Company of Senegal (SONES), Societe Nationale des Eaux de S\u00e9n\u00e9gal, and is
responsible for water supply and sanitation services in urban areas?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 13,
    "Question": "What was the name of the policy letter that expressed the government's
commitment to 'promote' and develop alternative on-site or conditional sanitation
systems in peri-urban neighborhoods and to develop partnerships with small-scale
private enterprise?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 14,
    "Question": "What was one of the key initiatives that was initiated under the Long
Term Water Sector Project (PLT)?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 15,
    "Question": "How many household sanitation facilities were constructed during the
pilot phase of the Sanitization Program for Peri-Urban Areas (PAQPUD) of Dakar?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 16,
    "Question": "What are some key factors that worked in PAQPUD's favor as mentioned
under 'Key Factors'?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 17,
    "Question": "How do you think the information from this context can be used for
real- world situations or problems?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 18,
    "Question": "What is one of the main reasons why the government decided to look for
alternative solutions for extending sewerage facilities in Dakar?",
    "Question_Type": "Inference"
  },
  {
    "Sl_no": 19,
    "Question": "Who was the executing agency of PAQPUD, and what were they
sub-contracted from?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 20,
    "Question": "What is one of the primary objectives of the 'Sanitation Program for
Peri-Urban Areas of Dakar' (PAQPUD)?",
    "Question_Type": "Inference"
  }
]



12.[
{
    "Sl_no": 1,
    "Question": "What is the title of the document titled on the slide?",
    "Question_Type": "Factual"
},
{
    "Sl_no": 2,
    "Question": "How many countries were analyzed in this report?",
    "Question_Type": "Analytical"
},
{
    "Sl_no": 3,
    "Question": "What was the goal of the transformation assessment in this context?",
    "Question_Type": "Summary"
},
{
    "Sl_no": 4,
    "Question": "What is the main title of the document in this context, which also
contains a subtitle?",
    "Question_Type": "Summary"
},
{
    "Sl_no": 5,
    "Question": "According to the report, what percentage of women are self-employed or
engaged in agriculture or services across low- and middle-income countries?",
    "Question_Type": "Factual"
},
{
    "Sl_no": 6,
    "Question": "Which group is concentrated in informal employment: women, men, or
both equally?",
    "Question_Type": "Summary"
},
{
    "Sl_no": 7,
    "Question": "What was the main goal of the transformation pathway",
    "Question_Type": "Analytical"
},
{
    "Sl_no": 8,
    "Question": "According to this context, what is the main title of the report?",
    "Question_Type": "Factual"
},
{
    "Sl_no": 9,
    "Question": "How many years was the data from the McKinsey Global Institute Power
of Parity Report based on?",
    "Question_Type": "Analytical"
},
{
    "Sl_no": 10,
    "Question": "What is a transformation pathway in this context?",
    "Question_Type": "Summary"
},
{
    "Sl_no": 11,
    "Question": "What were the top five countries that have made step-charge gains in
WEE outcomes, and what was the main driver of progress?",
    "Question_Type": "Analytical"
},
{
    "Sl_no": 12,
    "Question": "What is a transformation diagnostic for a country/region?",
    "Question_Type": "Summary"
},
{
    "Sl_no": 13,
    "Question": "What are the three steps of the WEE pathway in this context",
    "Question_Type": "Analytical"
},
{
    "Sl_no": 14,
    "Question": "What is the first step of the WEE pathway?",
    "Question_Type": "Summary"
},
{
    "Sl_no": 15,
    "Question": "Which region has the largest range in unpaid care work distribution?",
    "Question_Type": "Factual"
},
{
    "Sl_no": 16,
    "Question": "According to this context, what is a strong element for women's
economic empowerment",
    "Question_Type": "Summary"
},
{
    "Sl_no": 17,
    "Question": "What are the three types of training that can be combined with
vocational job training?",
    "Question_Type": "Factual"
},
{
    "Sl_no": 18,
    "Question": "How many percentage points lower was the rate of child marriage among
girls who lived near a garment factory in Bangladesh than those living far away from
it?",
    "Question_Type": "Factual"
},
{
    "Sl_no": 19,
    "Question": "What is a transformation pathway for women's economic empowerment",
    "Question_Type": "Summary"
},
{
    "Sl_no": 20,
    "Question": "Why was the country case study on Bolivia important in this context?",
    "Question_Type": "Inference"
}
]




13.[    {
        "Sl_no": "1",
        "Question": "What was the objective of the document titled 'Purpose of this
Document' that is shared in this context?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "2",
        "Question": "In which countries was the data used to understand the trend of
reducing legal hurdles that impede women's employment opportunities in Sub-Asia and
South Asia? ",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "3",
        "Question": "What are the three main categories of the elements included in
Step 2, according to this context?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "4",
        "Question": "What are the two steps that the document uses as a framework for
its methodology?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "5",
        "Question": "The Step 1 is divided into three main categories. What are these
categories, based on this context?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "6",
        "Question": "According to the source cited in the infographic, what was the
effect of a study from 2008 that discussed the impact of paid parental leave on female
labor force participation in developed economies? ",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "7",
        "Question": "What is the main difference between the 'Access to formal and
informal work opportunities' section and the 'Link to access to formal and informal
work' section, based on this infographic?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "8",
        "Question": "Is there a country-specific trend in the legal framework of South
Asia that is not mentioned in this context?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "9",
        "Question": "The infographic suggests that maternity leave in SSA and India has
a different percentage. How much does the percentage differ from the one mentioned for
the SSA region as a whole? Why might there be this difference?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "10",
        "Question": "Why do men tend to have lower female labor force participation
rates in countries where women are protected by legislation, according to this
infographic? What could be the underlying reason?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "11",
        "Question": "What is the main issue with regard to maternity leave in India
that the context mentions?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "12",
        "Question": "The infographic notes that the 2011-2014 data used for this study
was based on a limited number of countries. What were these countries? Why is it not
representative? Are there other limitations in using ILO surveys?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "13",
        "Question": "According to the infographic, what percentage of older women in
South Asia receive pensions? Is this better than or worse than their counterparts in
Europe and Central Asia? How does this compare to the situation in other regions?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "14",
        "Question": "What are the three main sections of the infographic?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "15",
        "Question": "How can an employer in India make sure that women have incentives
to hire and retain them? Why might this be necessary for some employers?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "16",
        "Question": "What is the main trend of reducing legal hurdles across various
regions, as suggested by the infographic? ",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "17",
        "Question": "What would happen if the 2011-2014 data used in this study was
based on a larger number of countries?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "18",
        "Question": "According to the infographic, what percentage of women in India
are engaged in agriculture? What is the main trend mentioned for the Indian
agricultural sector? Is this higher or lower than the global average for SSA?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "19",
        "Question": "What is the implication of the fact that women, globally, earn 23%
less than men? What might be some underlying reasons for this difference?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": "20",
        "Question": "In which two regions was there a decline in legal hurdles
affecting women's employment opportunities in the years 1960 and 2021, according to the
infographic? Why might this be the case?",
        "Question_Type": "Summary"
    }
]




14.[
{
"Sl_no":1,
"Question":"What is the purpose of the document titled \"Women's Economic Empowerment
(WEE) Transformation Assessment\"?",
"Question_Type":"Factual"
},
{
"Sl_no":2,
"What are the two main objectives mentioned in the first section of the context?",
"Question_Type":"Factual"
},
{
"Sl_no":3,
"What is the title of the first main point in the second section of the context?",
"Question_Type":"Factual"
},
{
"Sl_no":4,
"What does the document suggest about the relationship between unpaid care work and
women's economic empowerment?",
"Question_Type":"Analysis"
},
{
"Sl_no":5,
"What are the key takeaways from the infographic titled \"CONTENTS\" which is part of a
presentation? What can be inferred about the content?",
"Question_Type":"Summary"
},
{
"Sl_no":6,
"How does the section labeled \"Alleviating the Unpaid Care Burden Dramatically
Increases LFP, Wages and Quality of Jobs\" explain the impact on education outcomes,
access to work and legal rights?",
"Question_Type":"Explanation"
},
{
"Sl_no":7,
"What is the color-coding system used in the infographic titled \"UNPAID CARE WORK IS
LINKED TO EDUCATION OUTCOMES, ACCESS TO WORK, AND LEGAL RIGHTS\"? What can be inferred
from this title?",
"Question_Type":"Comparison"
},
{
"Sl_no":8,
"How does the section titled  \"GENDER GAP IN PENSIONS IS WORST IN MENA, WHILE SSA AND
SOUTH ASIA HAVE RELATIVELY SMALL GAPS.\" explain gender gaps in pensions",
"Question_Type":"Explanation"
},
{
"Sl_no":9,
"What is the purpose of the infographic titled  \"GUARANTEED MATERNITY LEAVE CAN HAVE
POSITIVE EFFECTS ON FEMALE LFP RATES, BUT IT MUST BE IMPLEMENTED PROPERLY\"? What are
some challenges in implementing this practice?",
"Question_Type":"Comparison"
},
{
"Sl_no":10,
"How does the section labeled  \"WOMEN'S WORK TENDS TO BE MORE VULNERABLE AND LESS
LUCRATIVE THAN MEN'S.\" explain the nature of women's work and its impact on the labor
market",
"Question_Type":"Explanation"
},
{
"Sl_no":11,
"What is the main message in the infographic titled  \"WOMEN'S WORK IS GENERALLY MORE
VULNERABLE AND LESS LUCRATIVE THAN MEN'S.\"\nWhat are some potential causes for the
challenges faced by women? What can be done to address these issues?",
"Question_Type":"Explanation"
},
{
"Sl_no":12,
"What is the main message in the infographic titled  \"THE NATURE OF INFORMAL WORK IS
CHANGING, WITH RAPID GROWTH OF ON-DEMAND SERVICES\"? What are some of the potential
causes and effects mentioned for these changes?",
"Question_Type":"Explanation"
},
{
"Sl_no":13,
"How does the section on "AVENUES FOR GE TEAM'S FUTURE EXPLORATION (D2)." propose to
further explore an area related to women's economic empowerment strategy? What are some
of the potential advantages or disadvantages for this approach?",
"Question_Type":"Application"
},
{
"Sl_no":14,
"What is the main message in the infographic titled  \"THE NATURE OF INFORMAL WORK IS
CHANGING, WITH RAPID GROWTH OF ON-DEMAND SERVICES\"? What are some of the potential
causes and effects mentioned for these changes?",
"Question_Type":"Explanation"
},
{
"Sl_no":15,
"Why is it important to understand the relationship between legal protections in the
workplace and economic outcomes. How can these two areas be compared? What is the
implication of the correlation between legal provisions regarding family status during
hiring and female labor force participation",
"Question_Type":"Application"
},
{
"Sl_no":16,
"What is the main message from the section titled  \"WOMEN'S LEGAL PROTECTIONS IN THE
WORKPLACE IMPROVE FLPWR, BUT IT MUST BE IMPLEMENTED PROPERLY.\"? How would the gender
gap in access to employment be addressed and what would be the implication on male
labor force participation if this strategy is adopted?",
"Question_Type":"Application"
},
{
"Sl_no":17,
"What are some of the policy issues mentioned in the context that affect women's
ability to get a pension? What can be done to address these challenges, assuming the
provision of maternity leave and family status inquiry are implemented effectively?",
"Question_Type":"Application"
},
{
"Sl_no":18,
"How do legal protections on prospective employers asking about family status compare
across South Asia and Sub- Saharan Africa? What is the implication for the female labor
force participation rates in these two regions if gender equality legislation is
implemented that requires a response from the employer. Can the gender gap be
attributed to the shift towards women's employment?",
"Question_Type":"Application"
},
{
"Sl_no":19,
"What are some of the reasons mentioned why there is no change in legal provisions on
maternity leave in the developed economies, despite having more favorable laws than
those that exist for low-income countries. How would this impact the female labor force
participation rates? What is the implication of such a gap in access to paid parental
leave for low-income countries?",
"Question_Type":"Inference"
},
{
"Sl_no":20,
"What are some of the suggestions mentioned by the context on how to address the
challenges faced by women, particularly if they have no experience or training and
cannot afford the costs associated with getting the training? How does it expect these
issues will be addressed? What is the implication for the future labor market in Sub-
Saharan Africa and South Asia?",
"Question_Type":"Inference"
}
]




15.[
{
"Sl_no": 1,
"Question": "What is Luwei Pearson's job?",
"Question_Type": "Factual"
},
{
"Sl_no": 2,
"Question": "How much does UNICEF spend per year for the health program in Ethiopia?",
"Question_Type": "Factual"
},
{
"Sl_no": 3,
"Question": "What is the top priority of Luwei Pearson's work at UNICEF, according to
this interview?",
"Question_Type": "Factual"
},
{
"Sl_no": 4,
"Question": "What are the three priorities of the Ethiopian health system that Luwei
Pearson suggests may provide an opportunity for improvement in MNCH according to this
interview? (i.e. Malaria, Diarrhea, and Pneumonia)?",
"Question_Type": "Factual"
},
{
"Sl_no": 5,
"Question": "What is a major challenge with the program that BMGF funds? (According to
Luwei Pearson)",
"Question_Type": "Factual"
},
{
"Sl_no": 6,
"Question": "What is one of the challenges with GAVI's provision of motorcycles for
health workers?",
"Question_Type": "Factual"
},
{
"Sl_no": 7,
"Question": "How much money does Luwei Pearson's team, UNICEF HPE, budget to spend on
each health post in a year in Ethiopia?",
"Question_Type": "Factual"
},
{
"Sl_no": 8,
"Question": "What is one of the major issues that UNICEF faces with regard to
supervision of Health Extension Workers?",
"Question_Type": "Factual"
},
{
"Sl_no": 9,
"Question": "Is there any major obstacle in the implementation of diarrheal disease
prevention program, according to this interview? (According to Luwei Pearson)",
"Question_Type": "Factual"
},
{
"Sl_no": 10,
"Question": "What is one of the main issues that affect quality of health service
delivery at hospitals and health centers?",
"Question_Type": "Factual"
},
{
"Sl_no": 11,
"Question": "According to Luwei Pearson, what are some of the factors that influence
the government? (i.e. UN organizations, PEPFAR, MDG Fund, NGO interventions)",
"Question_Type": "Factual"
},
{
"Sl_no": 12,
"Question": "What is one of the major issues with health extension workers according to
this interview?",
"Question_Type": "Factual"
},
{
"Sl_no": 13,
"Question": "Which three programs does UNICEF prioritize in Ethiopia? (According to
this interview)?",
"Question_Type": "Factual"
},
{
"Sl_no": 14,
"Question": "What is the major issue that Luwei Pearson suggests might be a challenge
with regard to the 48 hours after birth program funded by BMGF?",
"Question_Type": "Factual"
},
{
"Sl_no": 15,
"Question": "What are the two top priorities of the government's announcement with
regard to health post and HEW treatment? (According to this interview)",
"Question_Type": "Factual"
},
{
"Sl_no": 16,
"Question": "What is Luwei Pearson's role at UNICEF, according to this interview?",
"Question_Type": "Factual"
},
{
"Sl_no": 17,
"Question": "Does the government charge a fee for consumables at health centers?
(According to this interview)",
"Question_Type": "Factual"
},
{
"Sl_no": 18,
"Question": "How many supervisors does UNICEF have in total, according to this
interview?",
"Question_Type": "Factual"
},
{
"Sl_no": 19,
"Question": "What are the three areas of the health system that Luwei Pearson suggests
might not be sustainable and may not make sense if done by BMGF? (According to the
interview)",
"Question_Type": "Analytical"
},
{
"Sl_no": 20,
"Question": "How do you think the government's announcement of HEW treatment at Health
Posts will get better soon, in Luwei Pearson's view?",
"Question_Type": "Analytical"
}
]




16.[
    {
        "Sl_no":1,
        "Question":"What is the estimated market size for 3D printing technology in
2018?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":2,
        "Question":"What is the growth rate of the global 3D printing market during the
forecast period 2014-2020?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":3,
        "Question":"Who are the top three companies in the 3D printing industry?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":4,
        "Question":"What is the purpose of the 3D printing technology used by the
dental industry to create dental models and aligners? What benefits does this offer for
restorative labs?",
        "Question_Type":"Application"
    },
    {
        "Sl_no":5,
        "Question":"How do the different 3D printing technologies such as Selective
Laser Sintering (SLS) benefit the aerospace, automotive, healthcare, energy, and
jewelry industries? What is the purpose of this growth?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":6,
        "Question":"What are the top three factors driving companies to pursue 3D
printing technology? How do these differ from those that are driving adoption for
traditional 3D printing companies?",
        "Question_Type":"Comparison"
    },
    {
        "Sl_no":7,
        "Question":"When was the first stereolithographic machine launched by 3D
systems? What is the purpose of this, and how does it benefit the healthcare sector in
the long run?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":8,
        "Question":"What are the key activities that have contributed to the progress
of 3D printing technology since its invention in 1984? How do these developments impact
the growth of 3D printing in the healthcare sector?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":9,
        "Question":"What are some of the key advantages of using 3D bioprinting
technology to create cell patterns within confined spaces? What is the purpose of this,
and how does it aid in creating personalized 3D printed oral tablets?",
        "Question_Type":"Application"
    },
    {
        "Sl_no":10,
        "Question":"What are some of the key challenges faced by the healthcare sector
in adopting 3D printing technology, including bioprinting? What is the purpose of these
and what do they indicate about the need for more research or development on this
technology?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":11,
        "Question":"What are some of the key benefits that 3D printing offers over
traditional manufacturing in the healthcare sector? What is the purpose of this growth,
and what does it indicate for the market size?",
        "Question_Type":"Summary"
    },
    {
        "Sl_no":12,
        "Question":"How do different countries compare when it comes to their market
share in 3D printing technology during 2016? Which country has the highest market share
at 40%, and which is in the early stages of adopting this technology?",
        "Question_Type":"Factual"
    },
    {
        "Sl_no":13,
        "Question":"What are some of the key applications of 3D printing bioprinting in
tissue engineering, including its use for drug discovery and pre-clinical testing? What
is the purpose of these, and how do they benefit the healthcare sector?",
        "Question_Type":"Summary"
    },
    {
        "Sl_no":14,
        "Question":"What are some of the key applications of 3D printing technology in
the healthcare industry, including dental implants, prosthetics, tissue engineering,
medical models, and drugs? What is the purpose of this growth for the market size?",
        "Question_Type":"Summary"
    },
    {
        "Sl_no":15,
        "Question":"What are some of the key applications or products that Stratasys
offers in the healthcare sector, including dental applications? How do its patented
PolyJet and Fused Deposition Modeling (FDM) technology work?",
        "Question_Type":"Application"
    },
    {
        "Sl_no":16,
        "Question":"How does 3D printing bioprinting work? What are some of the
benefits it offers for pre-clinical testing, and how can this be used to create more
personalized 3D printed oral tablets?",
        "Question_Type":"Application"
    },
    {
        "Sl_no":17,
        "Question":"What is the key technology that EOS uses in Direct Metal Laser
Sintering (DMLS)? How does this differ from Fused Deposition Modeling, and what are
some of its applications, including 3D printed models for medical applications?",
        "Question_Type":"Application"
    },
    {
        "Sl_no":18,
        "Question":"What is the focus of Arcam's main market? What is the purpose of
this, and how do they intend to target this sector in terms of their products and
services portfolio?",
        "Question_Type":"Application"
    },
    {
        "Sl_no":19,
        "Question":"What are some of the key benefits that 3D printing technology
offers over traditional manufacturing for precision, function, and reliability? What is
the purpose of this growth, and what does it indicate about the market size?",
        "Question_Type":"Summary"
    },
    {
        "Sl_no":20,
        "Question":"What are some of the key applications or products that BioBots
offers in the tissue engineering sector? How do its patented Kenzan Method and 3D
printed bio materials work, including calcium chloride for curing bioink and BioKey for
curing bioink?",
        "Question_Type":"Application"
    }
]



17.[
    {
        "Sl_no": "1",
        "Question": "What is the name of the company that designed and owns the
Exemplars testing methodology and metrics?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "2",
        "Question": "How many main categories does the structured approach to defining
a product's exemplars have? And what are they?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "3",
        "Question": "What is the purpose of the three concentric circles in the diagram
that maps out the stages of testing for brand experience?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "4",
        "Question": "What are the three main columns with sub-columns that a structured
approach to defining a product's exemplars has? And what do these sub-columns
represent?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "5",
        "Question": "In the three concentric circles in the image, which circle
represents Content Test and what is it divided into?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "6",
        "Question": "What are the three main columns that a structured approach to
defining a product's exemplars has? And what do these sub-columns represent?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "7",
        "Question": "According to the diagram, how should a good brand experience for
users be characterized?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "8",
        "Question": "What is the first stage of the process suggested by the image in
defining the product's exemplars? And what is the name given to this stage?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "9",
        "Question": "The three columns have four quadrants each. What are these
quadrants labeled, and which one contains a list of tasks that must be completed to
define the product's exemplars?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "10",
        "Question": "Which column has metrics for evaluating the value of content
formatting, how it extends the value of content categories, and assessing the overall
look and feel of a content piece?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "11",
        "Question": "What are the three main columns that form the base for evaluating
the overall brand experience in the image? And what is the value of usability in the
context of this evaluation?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "12",
        "Question": "What is the purpose behind defining the product's exemplars as per
the image, and which stage does it end with according to the timeline or progression
suggested by the diagram?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "13",
        "Question": "The image also includes a logo. Which company is this logo from?
And what is the name of the source of the context that it indicates as copyrighted in
2017?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "14",
        "Question": "What are the three main columns that form the base for evaluating
a product's content test? And what metrics does each column have? What is the purpose
of each type of metric?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "15",
        "Question": "What do you think is the most valuable part of the content in
terms of creating a positive brand experience for users according to the image? And
what does this sentence mean: \"I am able to use the product easily.\"?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "16",
        "Question": "What are the five core testing stages and their corresponding
metrics suggested by the table for evaluating a product's content, format, and
features?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "17",
        "Question": "The image suggests that to evaluate the effectiveness of content
in various stages of development from test and prioritization to deployment, a good
approach is to have three categories: Content Test, Interaction Test, and Service &
Delivery Test. What do these categories represent?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "18",
        "Question": "What are the four main columns that make up the 'Content' column
in the table? What is the purpose of each type of metric under this category?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "19",
        "Question": "The 'Format and Design' column has metrics for evaluating the
value of content formatting, how it extends the value of content categories, assessing
typologies for content user-defined categories. What is the purpose of this type of
metric?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": "20",
        "Question": "What are the three main columns that form the base for evaluating
a product's interaction test? And what metrics does each column have? What is the
purpose of each type of metric in this context?",
        "Question_Type": "Summary"
    }
]


18.[
    {
        "Sl_no": 1,
        "Question": "What was the purpose of this presentation?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 2,
        "Question": "According to this presentation, who would be the largest single
party in the UP assembly elections?",
        "Question_Type": "Inference"
    },
    {
        "Sl_no": 3,
        "Question": "What is the name of the company or organization responsible for
this presentation?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 4,
        "Question": "What was the main heading in large font on one slide of the
presentation?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 5,
        "Question": "Which color is used for the background and text in this
presentation?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 6,
        "Question": "What does the logo at the bottom of the presentation indicate?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 7,
        "Question": "On which date was this document published?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 8,
        "Question": "What is the name of the organization responsible for the
presentation or event mentioned on the slide?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 9,
        "Question": "According to this context, what was the main focus of this
presentation?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 10,
        "Question": "How would you describe the overall layout of the presentation?",
        "Question_Type": "Analytical"
    },
    {
        "Sl_no": 11,
        "Question": "According to this context, what color was used for the text and
background of this presentation?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 12,
        "Question": "What does the logo at the bottom indicate?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 13,
        "Question": "Who is the leader of the Samajwadi Party in the context of the pre
and post election analysis presented here?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 14,
        "Question": "According to this presentation, which party won a massive
victory?",
        "Question_Type": "Inference"
    },
    {
        "Sl_no": 15,
        "Question": "What was the name of the political alliance with the Bharatiya
Janata Party in Punjab as indicated on the map?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 16,
        "Question": "According to this presentation, which party won 45 seats in the
Punjab legislative assembly in the 2012 election?",
        "Question_Type": "Inference"
    },
    {
        "Sl_no": 17,
        "Question": "What does the color blue represent on the map of Punjab?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 18,
        "Question": "According to this presentation, which party is expected to form a
government in the Rajya Sabha?",
        "Question_Type": "Summary"
    },
    {
        "Sl_no": 19,
        "Question": "What is the name of the organization whose logo is displayed at
the bottom right corner?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": 20,
        "Question": "What was the title of the presentation mentioned in this
context?",
        "Question_Type": "Factual"
    }
]



19.[
{
"Sl_no": 1,
"Question": "What is the SWEDD initiative?",
"Question_Type": "Factual"
},
{
"Sl_no": 2,
"Question": "Who attended the meeting or conference as indicated by the flags at the
bottom of the page?",
"Question_Type": "Factual"
},
{
"Sl_no": 3,
"Question": "What is the SWEDD component, which has started and developed an action
plan, validated by the steering committee?",
"Question_Type": "Factual"
},
{
"Sl_no": 4,
"Question": "What are the two main priorities for the Sahel countries as described in
the context",
"Question_Type": "Analytical"
},
{
"Sl_no": 5,
"Question": "According to the context, what is the main focus of the SWEDD
initiative?",
"Question_Type": "Summary"
},
{
"Sl_no": 6,
"Question": "What are some of the challenges that the Sahel countries face as described
in the first section of the context",
"Question_Type": "Summary"
},
{
"Sl_no": 7,
"Question": "According to the context, what is one of the main priorities for the Sahel
region?",
"Question_Type": "Factual"
},
{
"Sl_no": 8,
"Question": "What are some of the challenges that the Sahel countries face as described
in the first section of the context",
"Question_Type": "Summary"
},
{
"Sl_no": 9,
"Question": "The SWEDD component is focused on improving what?",
"Question_Type": "Factual"
},
{
"Sl_no": 10,
"Question": "What are some of the challenges that the Sahel countries face as described
in the first section of the context",
"Question_Type": "Summary"
},
{
"Sl_no": 11,
"Question": "According to the context, how is the SWEDD component focused on improving
demand?",
"Question_Type": "Explanation"
},
{
"Sl_no": 12,
"Question": "What are some of the challenges that the Sahel countries face as described
in the first section of the context",
"Question_Type": "Summary"
},
{
"Sl_no": 13,
"Question": "According to the second and third sections of the context, what are some
of the main steps or actions being taken to improve the supply chain?",
"Question_Type": "Analytical"
},
{
"Sl_no": 14,
"Question": "What is one of the main ways that the SWEDD component will improve the
supply chain as described in the fourth and fifth sections of the context?",
"Question_Type": "Explanation"
},
{
"Sl_no": 15,
"Question": "The SWEDD component is focused on improving what, according to the fifth
section of the context",
"Question_Type": "Factual"
},
{
"Sl_no": 16,
"Question": "What are some of the main ways that the Sahel countries can improve their
supply chain as described in the fourth and fifth sections of the context",
"Question_Type": "Explanation"
},
{
"Sl_no": 17,
"Question": "The SWEDD component will improve the supply chain by focusing on what,
according to the sixth section of the context",
"Question_Type": "Factual"
},
{
"Sl_no": 18,
"Question": "What are some of the main ways that the Sahel countries can improve their
supply chain as described in the sixth section of the context",
"Question_Type": "Explanation"
},
{
"Sl_no": 19,
"Question": "According to the SWEDD component, what will be the focus at the regional
level?",
"Question_Type": "Factual"
},
{
"Sl_no": 20,
"Question": "What are some of the main ways that the Sahel countries can improve their
supply chain as described in the sixth section of the context",
"Question_Type": "Explanation"
}

]



20.[
  {
    "Sl_no": 1,
    "Question": "What is the title of the first slide?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 2,
    "Question": "What are the main topics discussed in the slides?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 3,
    "Question": "Which foundation is responsible for the content of this document?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 4,
    "Question": "What is the main subject matter of the slides?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 5,
    "Question": "What are the objectives for today's discussion?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 6,
    "Question": "How does the pentavalent market analysis mainly focus on GAVI supply
strategies, plannings and the supplier investments in the slides?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 7,
    "Question": "Which four strategies are presented to reduce pricing",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 8,
    "Question": "How does the pentavalent market analysis mainly focus on GAVI supply
strategies in the slides?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 9,
    "Question": "What is the main purpose of the GAVI project also mentioned in the
slides?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 10,
    "Question": "Which four strategies are presented to reduce pricing according to the
slide titled 'Four key drivers will determine long-termm (2015+) price'?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 11,
    "Question": "Who is responsible for the penta market analysis in the slides?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 12,
    "Question": "Which four types of drivers are presented to determine long-term
pricing according to the slide titled 'Four key drivers will determine long-termm
(2015+) price'?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 13,
    "Question": "What is the name of the company that analyzed the potential market
power of the low-cost EM suppliers according to the slide titled 'Low-Cost EM
Suppliers'?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 14,
    "Question": "How much can a manufacturer margin potentially be reduced to in the
long-term if all the volume is shifted to only three lowest cost extended market
suppliers according to the slide titled 'Theoretically possible to begin leveraging
volume now - more robust data required to assess'?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 15,
    "Question": "What is the name of the organization that provided the slides? If
known, what year did it provide the document?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 16,
    "Question": "How much can a manufacturer margin potentially be reduced to in the
long-term if all the volume is shifted to only three lowest cost extended market
suppliers according to the slide titled 'Four key drivers will determine long-termm
(2015+) price'?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 17,
    "Question": "What are the four strategies for reducing margin presented in the
slides? If known, what year was this analysis done or when were the slides created?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 18,
    "Question": "Which four types of drivers are used to determine long-term pricing in
the slide titled 'Four key drivers will determine long-termm (2015+) price'?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 19,
    "Question": "What is the main purpose of the slides? If known, what year was this
analysis done or when were the slides created?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 20,
    "Question": "How will a shift to hexa affect GAVI's country plans for transition
from penta to hexa according to the slide titled 'Hexa development could influence
choice of penta suppliers - more data needed to fully assess'?",
    "Question_Type": "Inference"
  }
]


21.[
{"Sl_no":1,"Question":"What is the purpose of the slides that explain the pentavalent
market analysis which mainly focuses on GAVI supply strategies, plannings for upcoming
years and the supplier investments?","Question_Type":"Factual"},
{
"Sl_no":2,
"Question":"What are the four key drivers that will determine long-term 2015 pricing?",
"Question_Type":"Factual"
},
{
"Sl_no":3,
"Question":"What is the first bullet point on a slide from a presentation, likely used
in a business context? What does it suggest about the topic of the presentation?",
"Question_Type":"Analytical"
},
{
"Sl_no":4,
"Question":"What are the three main topics covered on a slide with the title 'Contents'
at the top? What do these indicate about the content of the slide?",
"Question_Type":"Summary"
},
{
"Sl_no":5,
"Question":"What does the second point under a section titled 'Margin example 2'
suggest about the market for Measles monovalent vaccine?",
"Question_Type":"Analytical"
},
{
"Sl_no":6,
"Question":"According to the text, what is the first point on a slide that addresses
managing market risks in supply chains?",
"Question_Type":"Analytical"
},
{
"Sl_no":7,
"Question":"What is the title of an infographic that discusses strategies for
mitigating risk in the context of leveraging volume to lower prices? What does this
suggest about the content and audience of the image?",
"Question_Type":"Analytical"
},
{
"Sl_no":8,
"Question":"According to a slide from a presentation, what are the three potential ways
to reduce price risk in supply chains?",
"Question_Type":"Summary"
},
{
"Sl_no":9,
"Question":"What is the title of a column on a slide that discusses strategies for
mitigating risk? What does this imply about the purpose of the slide and its
audience?",
"Question_Type":"Factual"
},
{
"Sl_no":10,
"Question":"According to a slide from a presentation, what are the potential benefits
in the Tender stage? In the Post-tender stage?",
"Question_Type":"Analytical"
},
{
"Sl_no":11,
"Question":"What is the main idea behind using a grid as described on an image? What
does this suggest about the content and audience of the image?",
"Question_Type":"Factual"
},
{
"Sl_no":12,
"Question":"According to the text, what are the six types of presentations that can be
awarded for Measles monovalent vaccine? In 2009, what is the pricing in these markets?
What does this suggest about the market dynamics?",
"Question_Type":"Analytical"
},
{
"Sl_no":13,
"Question":"What is the title of a slide that addresses managing market risks in supply
chains? What are some of its main ideas or strategies for mitigating price risk?",
"Question_Type":"Summary"
},
{
"Sl_no":14,
"Question":"According to an infographic, what does the second point under 'Illustrative
Alternatives to Mitigate Risk' suggest about the impact of a shift to EM supply base?
What are the two potential illustrations mentioned?",
"Question_Type":"Analytical"
},
{
"Sl_no":15,
"Question":"What is the title of the main section on an infographic that categorizes
different procurement processes based on the level of formality and informality
involved in data collection or interactions with suppliers? What does this suggest
about the content and audience of the image?",
"Question_Type":"Factual"
},
{
"Sl_no":16,
"Question":"What are the three main sections discussed on an infographic that addresses
the topic of multi-dose assessment in the pharmaceutical industry? How do these relate
to each other?",
"Question_Type":"Summary"
},
{
"Sl_no":17,
"Question":"What is a key point mentioned about the potential impact of a shift to hexa
on the supply landscape of pentavalent vaccines? What does this imply about the role
that the development of a hexavalent vaccine might have in penta vaccine supply?",
"Question_Type":"Factual"
},
{
"Sl_no":18,
"Question":"What is a key point mentioned about an infographic that discusses the topic
of multi-dose assessment in the pharmaceutical industry? How does this relate to other
ideas presented on the infographic? What do these suggest about the content and
audience of the image?",
"Question_Type":"Factual"
},
{
"Sl_no":19,
"Question":"What is a key point mentioned about an infographic that addresses the topic
of multi-dose assessment in the pharmaceutical industry? How does this relate to other
ideas presented on the infographic? What do these suggest about the content and
audience of the image?",
"Question_Type":"Factual"
},
{
"Sl_no":20,
"Question":"What is the potential impact on the market for penta vaccine suppliers if
some suppliers shift their focus from producing penta vaccines to hexa vaccines?",
"Question_Type":"Summary"
}

]



22.[
        {
        "Sl_no": 1,
        "Question": "How deeply involved is your organization into research into global healt
health?",
        "Question_Type": "Factual"
        },
        {
        "Sl_no": 2,
        "Question": "In what ways do you apply what you learned to your work? What types of d
data, learnings and takeaways seem useful?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 3,
        "Question": "How likely are you (your staff) to: a) Apply what you learned to your wo
work? b) What ways don't you do? What would be an example?",
        "Question_Type": "Factual"
        },
        {
        "Sl_no": 4,
        "Question": "What sections do you think most clear and easy to understand? Were any s
sections you felt were unclear? If so, for what reasons?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 5,
        "Question": "In three words, how would you describe the tone and style of descriptions
- Why? Why? why? (Probe on expand most interesting)",
        "Question_Type": "Factual"
        },
        {
        "Sl_no": 6,
        "Question": "What is anything that surprised you most about conclusions drawn in the 
content that you read?",
        "Question_Type": "Inference"
        },
        {
        "Sl_no": 7,
        "Question": "Where are any sections that felt out of place to you? If so, why? In what
way?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 8,
        "Question": "Overall, what would you compare the content on this site to other online
global health resources? In What ways are they different? How are they similar?",
        "Question_Type": "Comparison"
        },
        {
        "Sl_no": 9,
        "Question": "Did you find the video useful in giving you more confident understanding
of the topic? Is so, in what ways? If not, why?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 10,
        "Question": "Did the downloadable resources appear to be used to you? Was on the Stun
Stunning Concept Framework (Key Learnings) something you can work with? So, what
ways?",
        "Question_Type": "Summary"
        },
        {
        "Sl_no": 11,
        "Question": "Was the Stunning conceptual page (played in a way that gave you a lot of
information about learning and takeaways) successful different in your work? If so,
what was it?",
        "Question_Type": "Explanation"
        },
        {
        "Sl_no": 12,
        "Question": "What additional resources would you have liked to see that you didn't see
available on the site? What purpose do you think they would serve?",
        "Question_Type": "Application"
        }
]
```


```
[
        {
        "Sl_no": 13,
        "Question": "How likely are you (your staff) to:\n   a) Apply what you learned to your
work?\n   b) What ways don't you do? What would be an example?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 14,
        "Question": "What sections do you think most clear and easy to understand?",
        "Question_Type": "Summary"
        },
        {
        "Sl_no": 15,
        "Question": "Were any sections you felt were unclear? If so, for what reasons?",
        "Question_Type": "Application"
        }
]
```


```
[
        {
        "Sl_no": 16,
        "Question": "In three words, how would you describe the tone and style of descriptions
- Why? Why? why? (Probe on expand most interesting)",
        "Question_Type": "Factual"
        },
        {
        "Sl_no": 17,
        "Question": "What is anything that surprised you most about conclusions drawn in the 
content that you read?",
        "Question_Type": "Inference"
        }
]
```


```
[
        {
        "Sl_no": 18,
        "Question": "Where are any sections that felt out of place to you? If so, why? In what
way?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 19,
        "Question": "Overall, what would you compare the content on this site to other online
global health resources? In What ways are they different? How are they similar?",
        "Question_Type": "Comparison"
        }
]
```


```
[
        {
        "Sl_no": 20,
        "Question": "Did you find the video useful in giving you more confident understanding
of the topic? Is so, in what ways? If not, why?",
        "Question_Type": "Application"
        },
        {
        "Sl_no": 21,
        "Question": "Did the downloadable resources appear to be used to you? Was on the Stun
Stunning Concept Framework (Key Learnings) something you can work with? So, what
ways?",
        "Question_Type": "Summary"
        }
]
```


```
[
        {
        "Sl_no": 22,
        "Question": "Was the Stunning conceptual page (played in a way that gave you a lot of
information about learning and takeaways) successful different in your work? If so,
what was it?",
        "Question_Type": "Explanation"
        },
        {
        "Sl_no": 23,
        "Question": "What additional resources would you have liked to see that you didn't see
available on the site? What purpose do you think they would serve?",
        "Question_Type": "Application"
        }
]



23.[
{
"Sl_no": 1,
"Question": "What was the main concept that Bill and Melinda Gates Foundation supported
in 2013?",
"Question_Type": "Factual"
},
{
"Sl_no": 2,
"What is the main focus of the 'GH Drug Accelerator' as mentioned in the context?",
"Question_Type": "Factual"
},
{
"Sl_no": 3,
"In which year was the concept of 'GH Drug Accelerator' introduced?",
"Question_Type": "Factual"
},
{
"Sl_no": 4,
"What is the logo at the bottom right corner of the image indicating the organization
that supported this concept?",
"Question_Type": "Factual"
},
{
"Sl_no": 5,
"The concept of 'GH Drug Accelerator' was introduced in which year and what is the main
goal of this initiative?",
"Question_Type": "Analytical"
},
{
"Sl_no": 6,
"What are the diseases that the drug pipeline is insufficient for as per the context?",
"Question_Type": "Summary"
},
{
"Sl_no": 7,
"What is the framework in which the 'GH Drug Accelerator' concept can be seen as being
presented to an audience, possibly during a presentation or meeting of the
foundation?",
"Question_Type": "Summary"
},
{
"Sl_no": 8,
"The four quadrants that are used in this conceptual framework are what and why were
they so named?",
"Question_Type": "Explanation"
},
{
"Sl_no": 9,
"What is the goal for the 'GH Drug Accelerator' as mentioned in the context?",
"Question_Type": "Summary"
},
{
"Sl_no": 10,
"The approach to speed up the drug development process involves harnessing what and
organizing which capabilities?",
"Question_Type": "Explanation"
},
{
"Sl_no": 11,
"What are the PSTD/PD priorities mentioned as part of the 'Approach' in the framework
for 'GH Drug Accelerator' that is expected to lead to improvements at each stage of the
drug discovery and development pipeline?",
"Question_Type": "Summary"
},
{
"Sl_no": 12,
"The expected outcomes from the 'Approach' in the conceptual framework include what by
what time?",
"Question_Type": "Explanation"
},
{
"Sl_no": 13,
"What are the four quadrants that make up the conceptual framework for the 'GH Drug
Accelerator', and what is the purpose of each quadrant?",
"Question_Type": "Summary"
},
{
"Sl_no": 14,
"The two main approaches to drug discovery in the infographic include what on either
side, with what colors?",
"Question_Type": "Summary"
},
{
"Sl_no": 15,
"What are the three circular nodes that represent stages of drug discovery in the
disease-relevant assays section of the infographic?",
"Question_Type": "Summary"
},
{
"Sl_no": 16,
"This section is color coded primarily with what two colors?",
"Question_Type": "Comparison"
},
{
"Sl_no": 17,
"What are the three circular nodes on the left side of the infographic, and which
diseases do they represent?",
"Question_Type": "Factual"
},
{
"Sl_no": 18,
"This section is color coded primarily with what two colors?",
"Question_Type": "Comparison"
},
{
"Sl_no": 19,
"The main theme that this slide is based on to streamline the drug development process
is what and what is its goal as mentioned in the context?",
"Question_Type": "Explanation"
},
{
"Sl_no": 20,
"What are the three circular nodes on the right side of the infographic, and which
chemistry types do they represent?",
"Question_Type": "Factual"
}
]



24.[{"Sl_no":1,"Question":"What is the origin of pooled
funds?","Question_Type":"Factual"}]
[{"Sl_no":2,"Question":"Who manages the Pooled Fund
(PBS)?"","Question_Type":"Factual"}]
[{"Sl_no":3,"Question":"How was the funding for Phase 2 of PBS
allocated?","Question_Type":"Factual"}]
[{"Sl_no":4,"Question":"What is the role of donors in managing the pooled
funds?","Question_Type":"Factual"}]
[{"Sl_no":5,"Question":"Why did the US Government have difficulty coordinating with
other donors on IHP+ process?"","Question_Type":"Factual"}]
[{"Sl_no":6,"Question":"What are the benefits that Protik (Suprotik) and Tedros expect
from the IHP+ process?","Question_Type":"Factual"}]
[{"Sl_no":7,"Summary_Q":1,"Question":"Summarize the background and overview of the UN
Special Envoy for Malaria as described by Suprotik Basu in his interview with Adrien de
Chaismartin and Tara Azimi."","Question_Type":"Summary"}]
[{"Sl_no":8,"Explanation_Q":1,"Question":"Explain how donors are aligned on funding for
the gaps identified by Tedros."","Question_Type":"Explanation"}]
[{"Sl_no":9,"Comparison_Q":1,"Question":"What are the differences in donor coordination
facilitated by IHP and HPN?","Question_Type":"Comparison"}]
[{"Sl_no":10,"Inference_Q":1,"Question":"How does Protik think Tedros' strong position
facilitates better alignment among donors?"","Question_Type":"Inference"}]
[{"Sl_no":11,"Summary_Q":2,"Question":"What are the major differences between Phase 1
and Phase 2 of Pooled Funds?","Question_Type":"Summary"}]
[{"Sl_no":12,"Application_Q":1,"Question":"How does Tedros' leadership help to
facilitate donor coordination on IHP+ process?"","Question_Type":"Application"}]
[{"Sl_no":13,"Inference_Q":2,"Question":"Why is the US Government perceived as out of
the loop in HPN?","Question_Type":"Inference"}]
[{"Sl_no":14,"Summary_Q":3,"Question":"What are the main reasons for Protik's
suggestion that IHP+ will bring two benefits?"","Question_Type":"Summary"}]
[{"Sl_no":15,"Application_Q":2,"Question":"How does Tedros' leadership facilitate
donors' better alignment on funding and what gaps does it
fill?","Question_Type":"Application"}]
[{"Sl_no":16,"Inference_Q":3,"Question":"What is the major difference between how FMOH
and PEPFAR engage the donor community?"","Question_Type":"Inference"}]
[{"Sl_no":17,"Summary_Q":4,"Question":"How does IHP+ process facilitate better
coordination among donors?","Question_Type":"Summary"}]
[{"Sl_no":18,"Comparison_Q":2,"Question":"What are the differences in donors'
perception of value-add from IHP and IHP+ processes?"","Question_Type":"Inference"}]
[{"Sl_no":19,"Evaluation_Q":1,"Question":"Is it true that all donors seem skeptical
about an expected increase in funding for the IHP+
process?","Question_Type":"Evaluation"}]
[{"Sl_no":20,"Synthesis_Q":1,"Question":"How does Suprotik (Protik) think that a donor
like BMGF can bring to scale new interventions through its investment and support to
HEWs?","Question_Type":"Synthesis"}]



25.[
        {
                "Sl_no": 1,
                "Question": "What is the name of the agency that receives budget authority from the
Congress and other agencies?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 2,
                "Question": "What is the name of the President's Malaria Initiative announced in 2005
by which the USAID achieved a reduction in infant mortality rates in six countries",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 3,
                "Question": "When was the Foreign Assistance Act signed into law?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 4,
                "Question": "How many countries were helped by the USAID to transition to a m
market-based economy between 1992 and 2015",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 5,
                "Question": "What is the name of the initiative that helps in developing sustainable
natural resource management through policies on land tenure related to forests,
wildlife, or water?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 6,
                "Question": "What is the percentage reduction in under-5 mortality USAID achieved in
their priority countries by 2015",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 7,
                "Question": "Who was the President of the United States when he signed the Foreign
Assistance Act into law?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 8,
                "Question": "What is the name of the organization that USAID works with to address
global health challenges, such as the COVID-19 pandemic and other zoonotic diseases?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 9,
                "Question": "What is the name of the organization in which the USAID plays a key role
in addressing global health challenges, such as the COVID-19 pandemic and other
zoonotic diseases?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 10,
                "Question": "What is the name of the initiative that helps to reduce the impact of
HIV/AIDS on human health and social stability",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 11,
                "Question": "How many countries have been helped by the USAID since 1992?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 12,
                "Question": "What is the name of the initiative that helps in reducing the impact on
human health and social stability",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 13,
                "Question": "The USAID has provided what number of people to access sustainable water
supply, and sanitation facilities between 1992 and 2015?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 14,
                "Question": "What is the name of the initiative that helps in reducing the risk of
natural disasters",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 15,
                "Question": "Who was the first interim Administrator of the USAID appointed by the
President?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 16,
                "Question": "When was the USAID founded",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 17,
                "Question": "Who is the current interim Administrator of the USAID?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 18,
                "Question": "What are the three key pillars that comprise the USAID's climate program",
                "Question_Type": "Analytical"
        },
        {
                "Sl_no": 19,
                "Question": "How many projects did the USAID execute between 1992 and 2015?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": 20,
                "Question": "What are the three main sections of the USAID's approach to disaster
assistance",
                "Question_Type": "Analytical"
        }
]



26.[
    {
        "Sl_no": "1",
        "Question": "What is MomConnect?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "2",
        "Question": "Which initiative was launched by the South African National
Department of Health (NDOH) to improve the health of pregnant women, newborns and
infants at national scale?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "3",
        "Question": "How does MomConnect use mobile technology to improve the health of
pregnant women in South Africa?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "4",
        "Question": "In what way can a woman register for the services offered by
MomConnect?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "5",
        "Question": "How does the registration process take place at a clinic and who
facilitates it? What role do health networks play in this process?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "6",
        "Question": "What is the purpose of the registration for MomConnect messaging?
How does the registration link to facility?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "7",
        "Question": "What information do pregnant women get via the stage-based
messaging offered by MomConnect? Up to what age is this information relevant and why?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "8",
        "Question": "Who can register for MomConnect services besides the expectant
mother, and which department of Health provides these services?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "9",
        "Question": "What are the two ways that a woman can rate her service at a
clinic? What is the purpose of these ratings?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "10",
        "Question": "Who has access to all decision makers who get real time
information on pregnancy registration, service rating and helpline data?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "11",
        "Question": "What are the five modules that support the MomConnect services for
expectant mothers? What is the purpose of these modules?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "12",
        "Question": "What is the first step that a nurse must do in order to sign up a
woman for MomConnect messages? Who helps her with this process and how does she do it?
How does registration happen across different clinics?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "13",
        "Question": "What is the purpose of the USSD menu in the first module for
registration, according to which every woman can get free information and also send a
question to a health expert?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "14",
        "Question": "Why do nurses have access to an SMS helpdesk with messages that
are tailored to clinical and psycho-social support? What is the purpose of these
messages for nurses?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "15",
        "Question": "What is the purpose of the Service Rating module, according to
which every service provider must get a rating from the mother she has attended in an
antenatal clinic? How are the ratings linked to the nurse and what happens when a
compliment or complaint is received?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "16",
        "Question": "What is the purpose of the Service Rating module? Why must every
service provider get a rating from the mother they have attended in an antenatal
clinic? How are the ratings linked to the nurse and what happens when a compliment or
complaint is received?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "17",
        "Question": "What information can a registered MomConnect user receive, besides
being informed about how to care for herself while pregnant, when to visit the clinic
and how to prepare for birth? How long does this information remain relevant?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "18",
        "Question": "What is the purpose of the Service Rating module? Why must every
service provider get a rating from the mother they have attended in an antenatal
clinic? How are the ratings linked to the nurse and what happens when a compliment or
complaint is received?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "19",
        "Question": "What role do all health service members (including nurses,
midwives, doctors etc) play in registering for MomConnect messages? What does the
Service Rating module do and how are the ratings linked to the nurse?",
        "Question_Type": "Factual"
    },
    {
        "Sl_no": "20",
        "Question": "What are some of the features that support nurses and central data
repositories, besides allowing them to view real time information on pregnancy
registration, service rating and helpline data at a national, provincial, district and
clinic level?",
        "Question_Type": "Factual"
    }
]



27.
[
{
"Sl_no": "1",
"Question": "What is the primary focus of David Pelletier's work in Ethiopia and
Bangladesh?",
"Question_Type": "Factual"
},
{
"Sl_no": "2",
"What were the two key challenges that the country-owners encountered when developing a
multi-sectoral plan for scaling up nutrition interventions?",
"Question_Type": "Factual"
},
{
"Sl_no": "3",
"Why is it important to assess a country's implementation capacity before making
decisions on what and how much resources to invest in any given intervention?",
"Question_Type": "Explanation"
},
{
"Sl_no": "4",
"What are the primary steps that David's society has taken to document the contextual
factors for an effective scale-up of nutrition interventions in Vietnam, Bangladesh and
Ethiopia as well as other countries?",
"Question_Type": "Explanation"
},
{
"Sl_no": "5",
"How is it possible to make a country-adopted and country-led process work with
multiple partners and donors involved in different parts of the process?",
"Question_Type": "Application"
},
{
"Sl_no": "6",
"What are the two important components that David's society has worked on during its
recent international meetings to boil down the information needed for a proposal from
the minister of health and other officials into a more easily digested format?",
"Question_Type": "Factual"
},
{
"Sl_no": "7",
"What are the three main goals that David's society is working towards in terms of the
global hub for nutrition interventions, which was conceived at Cornell University?",
"Question_Type": "Factual"
},
{
"Sl_no": "8",
"How has the country-owners' process been shaped by their experiences with the Scaling
Up Nutrition (SUN) movement, and what are the main outcomes that David's society hopes
to see in 2017 for this effort?",
"Question_Type": "Application"
},
{
"Sl_no": "9",
"What were some of the key findings and recommendations from the Lancet article about
the Scaling Up Nutrition (SUN) initiative in 2008, when it was first launched by
UNICEF? How did the SUN movement respond to these criticisms?",
"Question_Type": "Summary"
},
{
"Sl_no": "10",
"What is the range of decisions that are involved during the process of creating a
proposal for a country-adopted and country-led multi-sectoral plan for scaling up
nutrition interventions?",
"Question_Type": "Factual"
},
{
"Sl_no": "11",
"How does the country's implementation capacity affect the knowledge that is needed to
successfully implement any given intervention, in David's perspective?",
"Question_Type": "Explanation"
},
{
"Sl_no": "12",
"What were some of the specific challenges that the secretaries for the ministries of
health or the equivalent office faced during their monthly and bi-yearly meetings on
taking decisions related to the country-adopted and country-led process for scaling up
nutrition interventions?",
"Question_Type": "Summary"
},
{
"Sl_no": "13",
"What was the initial approach of the Foundation to support the country-owners' efforts
in Vietnam, Bangladesh and Ethiopia? What were some positive outcomes from this support
that David's staff documented?",
"Question_Type": "Factual"
},
{
"Sl_no": "14",
"Why is it important for a country to have a good understanding of its own capacity to
implement any given intervention before it decides on the kind of actions it should
take or the interventions that are required in order to achieve a specific goal?",
"Question_Type": "Explanation"
},
{
"Sl_no": "15",
"What was the purpose behind David's society convening government officials and other
partner organizations from different sectors in the same room during its recent
international meeting to discuss how they can work together on scaling up nutrition
interventions?",
"Question_Type": "Application"
},
{
"Sl_no": "16",
"Why is it important for the staff to document the contextual information about
implementation realities and the number and skill level of lower ranking staff at a
country level, in David's perspective?",
"Question_Type": "Explanation"
},
{
"Sl_no": "17",
"What were some of the differences between the way the Foundation approached its work
with UNICEF and the World Bank? How did these different relationships influence the
kinds of decisions that each made about what kind of actions to take or the
interventions they supported?",
"Question_Type": "Contrast"
},
{
"Sl_no": "18",
"How is it possible for countries to share the information they have gathered from
their own contextual assessments with other SUN member-countries and how does David
think this process will proceed in 2017?",
"Question_Type": "Application"
},
{
"Sl_no": "19",
"What are the three main components that the knowledge function encompasses, in David's
perspective? Why is this model important for a country-adopted and country-led approach
to scaling up nutrition interventions?",
"Question_Type": "Explanation"
},
{
"Sl_no": "20",
"How would you summarize the challenges that the country-owners' process of developing
multi-sectoral plans has faced so far in terms of David's perspective? What are some of
the most promising areas for positive change and improvement as a result of this
experience, in his opinion?",
"Question_Type": "Summary"
}
]


28.[
  {
    "Sl_no": 1,
    "Question": "What is the primary purpose of David Pelletier's staff?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 2,
    "Question": "How do David's staff get to know other actors in the SUN movement at
the country level?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 3,
    "Question": "What is the first step that a permanent secretary does when they meet
twice a year to take policy decisions as per David's observation?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 4,
    "Question": "Which country started to create a multi-organizational nutrition
working group for decision-making in its ministry? (according to David)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 5,
    "Question": "Who are the main informants that David's staff consult while they're
doing research on a country?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 6,
    "Question": "What is the purpose of creating a PPT document for an international
meeting in the view of David Pelletier?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 7,
    "Question": "According to David, who gives confidence to UNICEF or World Bank staff
to plan and implement a project at the country level? (Select one: government people
from various sectors or NGOs)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 8,
    "Question": "What is the main purpose of creating a 'war room' in David's office?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 9,
    "Question": "In what countries does SUN movement have an annual meeting to share
lessons? (Select one: all, some or none)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 10,
    "Question": "According to David, how often do the permanent secretaries meet to
take policy decisions?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 11,
    "Question": "What is the main function of a knowledge broker in SUN movement, as
mentioned by David Pelletier? (Select one: staff here are many donors, staff here are
few and small foundation)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 12,
    "Question": "Which three organizations does David's society work with for its
knowledge function?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 13,
    "Question": "What is the name of the organization that SUN movement country
secretariat in Geneva sends out a quarterly newsletter to? (Select one: UNICEF or World
Bank)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 14,
    "Question": "According to David, what type of document does he expect from the
permanent secretaries?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 15,
    "Question": "Which country was criticized for its approach in the Scaling Up
Nutrition (SUN) movement in 2008? (Select one: Vietnam, Bangladesh or Ethiopia)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 16,
    "Question": "What are the three types of knowledge functions mentioned by David for
implementation and planning of an intervention?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 17,
    "Question": "What are the two main components that make up a country's capacity to
implement, in the view of David Pelletier? (Select one: number and skill level, only
number or only skill level)",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 18,
    "Question": "What is the most important aspect that David considers as a knowledge
broker in the country level?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 19,
    "Question": "How do the permanent secretaries decide the budget for their
departments, according to David Pelletier? (Select one: they meet monthly but are
poorly planned, moderately and not decision-orientated or they have no meetings but
only twice a year)",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": 20,
    "Question": "Why does David think that the country's capacity to implement an
intervention is more important than knowing what kind of interventions are in place?",
    "Question_Type": "Factual",
  }
]


29.[{"Sl_no":1,"Question":"What is the focus of David Pelletier's staff when it comes to
assessing the context of implementation?","Question_Type":"Factual"}]
[{"Sl_no":2,"Question":"How much time does the staff spend assessing and understanding
the context of implementation?","Question_Type":"Factual"}]
[{"Sl_no":3,"Question":"What is another factor that affects the community, according to
David Pelletier's observation?","Question_Type":"Factual"}]
[{"Sl_no":4,"Question":"What are the two types of staff required to effectively
implement something at the country level?","Question_Type":"Factual"}]
[{"Sl_no":5,"Question":"Who do the knowledge brokers need to network into, according to
David Pelletier's observation?","Question_Type":"Factual"}]
[{"Sl_no":6,"Question":"What is the name of the movement that involves 57 countries and
has SUN secretariat in Geneva?","Question_Type":"Factual"}]
[{"Sl_no":7,"Question":"Which country, according to David Pelletier's observation, has
a ministry for nutrition but it is not the health
ministry?","Question_Type":"Factual"}]
[{"Sl_no":8,"Question":"How often do the
permanent secretaries meet to take policy decisions?","Question_Type":"Factual"}]
[{"Sl_no":9,"Question":"What level of planning are the monthly meetings and the
two-yearly meetings with the permanent secretaries, according to David Pelletier's
observation?","Question_Type":"Analytical"}]
[{"Sl_no":10,"Question":"What is the purpose of convening government people from
various sectors as well as different partner organizations in a country, as described
by David Pelletier?","Question_Type":"Summary"}]
[{"Sl_no":11,"Question":"Why does David' staff need to give them the confidence to do
that, according to his observation?","Question_Type":"Explanation"}]
[{"Sl_no":12,"Question":"What is an important process of the permanent secretaries, as
described by David Pelletier?","Question_Type":"Summary"}]
[{"Sl_no":13,"Question":"Who was the leader in the Scaling Up Nutrition movement that
had 2-year case studies to document its work?","Question_Type":"Factual"}]
[{"Sl_no":14,"Question":"What is the purpose of the 'war room' where David's staff need
to go, according to his observation?","Question_Type":"Explanation"}]
[{"Sl_no":15,"Question":"In which country does the multi- sectoral committee that meets
monthly with technical staff meet, as described by David
Pelletier?","Question_Type":"Factual"}]
[{"Sl_no":16,"Question":"How often do the permanent secretaries take policy
decisions?","Question_Type":"Factual"}]
[{"Sl_no":17,"Question":"Why did some of the sector secretaries start creating working
groups for nutrition within their own ministries, as described by David
Pelletier?","Question_Type":"Explanation"}]
[{"Sl_no":18,"Question":"Who chairs the nutrition working group that was created by
some of the permanent secretaries in their own ministries, according to David
Pelletier's observation?","Question_Type":"Factual"}]
[{"Sl_no":19,"Question":"What is one method of sharing information with the SUN
secretariat in Geneva?","Question_Type":"Factual"}]
[{"Sl_no":20,"Question":"Why does David think the governments do not pull down the
global knowledge to their country level, as described by
him?","Question_Type":"Explanation"}]


30.
[
  {
    "Sl_no": "1",
    "Question": "What is the purpose of the Breeding Program Assessment Tool (BPAT)?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "2",
    "Question": "The BPAT assessment process brings what numerous benefits to
institutions?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "3",
    "Question": "What are the components of a typical EIAr strategic plan?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "4",
    "Question": "How can the EiAR Director General and other internal auditors work
with the suggested locations to drive delivery of initiatives?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "5",
    "Question": "What is the main focus for the development and testing with
experienced breeders and pilot visits to five institutions at various dates for the
BPAT process?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "6",
    "Question": "What are the three main columns of the BPAT framework for plant
breeding projects?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "7",
    "Question": "What is the purpose of a program impact assessment in the context of
BPAT?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "8",
    "Question": "How can one determine if an institution' s bread wheat or chickpea
programs meet its goals? Why is this important to donors and other key stakeholders?",
    "Question_Type": "Comparison"
  },
  {
    "Sl_no": "9",
    "Question": "What are the potential benefits of using the BPAT process for
institutions?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "10",
    "Question": "What is the most significant factor that drives a public sector
breeding program' s ability to achieve higher rates of genetic gain? Why is this
important to donors and other key stakeholders?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "11",
    "Question": "What are some of the benefits that institutions can expect from using
the BPAT process for public sector breeding programs?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "12",
    "Question": "In your own words, what is the main focus for the development and
testing with experienced breeders and pilot visits to five institutions at various
dates for the BPAT process?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "13",
    "Question": "What are some of the benefits that institutions can expect from using
the BPAT process for public sector breeding programs? Why is it important to have a
well-defined process like BPAT in place before a large programmatic initiative
begins?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "14",
    "Question": "What are some of the benefits that institutions can expect from using
the BPAT process for public sector breeding programs? Why is it important to have an
assessment process like BPAT in place before a large programmatic initiative begins?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "15",
    "Question": "How do you see the development and testing of the BPAT process by
experienced breeders and pilot visits to five institutions at various dates impacting
the development of public sector breeding programs? Why is this important for donors
and other key stakeholders?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "16",
    "Question": "What are some of the factors that drive a public sector breeding
program's ability to achieve higher rates of genetic gain? What is the impact on donors
and other key stakeholders?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "17",
    "Question": "Why do you think the BPAT framework for plant breeding projects are
important?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "18",
    "Question": "What is the main focus of EIAr' s strategic planning? Why is this
important to donors and other key stakeholders?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "19",
    "Question": "How can one use information about the BPAT process in order to drive
delivery of initiatives for a public sector breeding program? What is the main focus
for the development and testing with experienced breeders and pilot visits to five
institutions at various dates?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "20",
    "Question": "What are some of the factors that drive a public sector breeding
program' s ability to achieve higher rates of genetic gain? Why is this important for
the donors and other key stakeholders?",
    "Question_Type": "Factual"
  }
]


31.[
        {
                "Sl_no": "1",
                "Question": "What is the primary purpose of the 'Data CODING' process?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "2",
                "Question": "How are data from different qualitative research instruments categorized
in this step?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "3",
                "Question": "What is the purpose of tagging and coding data with words or short phrases
that describe participant feedback on topics addressed by the discussion guide?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "4",
                "Question": "What are some adjectives characterizing participants' views of usefulness,
clarity, tone and style, order/ logic, comparable resources, specific resources and
additional resources?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "5",
                "Question": "How do data from qualitative research instruments get categorized in this
step?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "6",
                "Question": "What are some distinctive participant sentiments with respect to the topic
of 'Topics addressed in discussion guide' and what is their explanation for these
feelings?",
                "Question_Type": "Analytical"
        },
        {
                "Sl_no": "7",
                "Question": "What are the topics addressed by the discussion guide?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "8",
                "Question": "How do participants view the order/logic of this content section?",
                "Question_Type": "Analytical"
        },
        {
                "Sl_no": "9",
                "Question": "What is the purpose of 'Sorting' in this step?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "10",
                "Question": "How are tags/codes from data coding for occurrences sorted to get a high
level sense of most often repeated data points?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "11",
                "Question": "What is the primary goal of this step 'Sorting'?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "12",
                "Question": "How are data within top patterns shared sorted and what are some
consistent trends that characterize these patterns identified in this step?",
                "Question_Type": "Analytical"
        },
        {
                "Sl_no": "13",
                "Question": "What is the purpose of creating quick phrases to describe core sentiment
for each pattern?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "14",
                "Question": "What do persistent outliers have that is different from the focus of this
research and what are their potential implications or value?",
                "Question_Type": "Analytical"
        },
        {
                "Sl_no": "15",
                "Question": "What is the purpose of the 'External REVIEW' session in this process? How
does it support the team's efforts to analyze the context? ",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "16",
                "Question": "How do data patterns relate to other data sets?",
                "Question_Type": "Analytical"
        },
        {
                "Sl_no": "17",
                "Question": "What are the main steps of the 'Data Analysis' process in this context?",
                "Question_Type": "Summary"
        },
        {
                "Sl_no": "18",
                "Question": "What does this 'Exemplars Data Synthesis Process' guide for? What is it
used to do? ",
                "Question_Type": "Summary"
        },
        {
                "Sl_no": "19",
                "Question": "How can the 'Data Analysis Structure' be applied to other content testing
research projects?",
                "Question_Type": "Factual"
        },
        {
                "Sl_no": "20",
                "Question": "What are the goals and objectives of this process in general? What is its
purpose?  How does it help users with their own needs?",
                "Question_Type": "Summary"
        }
]


32.[
    {
      "Sl_no": 1,
      "Question": "What type of infections are chronic viral infections?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 2,
      "Question": "How has Gilead built expertise in the discovery and development of
antiviral nucleoside and nucleotide analogs to target viral RNA polymerases?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 3,
      "Question": "What are the three main categories of viruses that have been
approved with Gilead's expertise in the discovery and development of antiviral
nucleoside and nucleotide analogs to target viral RNA polymerases?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 4,
      "Question": "What does the timeline indicate?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 5,
      "Question": "Why is GS-5734 intended for future emergency use and clinical
testing, as well as to enable a 30-minute infusion?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 6,
      "Question": "What is the purpose of the image 'Summary'?",
      "Question_Type": "Summary"
    },
    {
      "Sl_no": 7,
      "Question": "What do the two main groups in the diagram labeled 'Summary'
indicate?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 8,
      "Question": "How is GS-5734 used to treat acute viral infections, as well as
chronic ones?",
      "Question_Type": "Summary"
    },
    {
      "Sl_no": 9,
      "Question": "What are the two main categories of antiviral drugs that have been
approved with Gilead's expertise in the discovery and development of antiviral
nucleoside and nucleotide analogs to target viral RNA polymerases?",
      "Question_Type": "Summary"
    },
    {
      "Sl_no": 10,
      "Question": "Why has Gilead built expertise in the discovery and development of
antiviral nucleoside and nucleotide analogs that has provided a platform for successful
regulatory approval of multiple antiviral products widely used for the treatment and
prevention of chronic viral infections including HIV, HBV, and HCV?",
      "Question_Type": "Summary"
    },
    {
      "Sl_no": 11,
      "Question": "What are the three main groups of viruses that have been identified
as being all RNA viruses?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 12,
      "Question": "Why is the diagram labeled 'Different Chemical Forms in the Same
Class'?",
      "Question_Type": "Summary"
    },
    {
      "Sl_no": 13,
      "Question": "What does Gilead's experience with clinical development of multiple
antiviral products widely used for the treatment and prevention of chronic viral
infections including HIV, HBV, and HCV suggest about Gilead?",
      "Question_Type": "Summary"
    },
    {
      "Sl_no": 14,
      "Question": "What is the purpose of this image 'Gilead Antiviral Program on
Emerging and Neglected Viruses'?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 15,
      "Question": "How do antivirals target viral RNA polymerases to inhibit their
activity?",
      "Question_Type": "Explanation"
    },
    {
      "Sl_no": 16,
      "Question": "What are the different types of viruses that have been identified as
being all RNA viruses?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 17,
      "Question": "How do antiviral nucleosides and nucleotides target viral RNA
polymerases to inhibit their activity?",
      "Question_Type": "Explanation"
    },
    {
      "Sl_no": 18,
      "Question": "What are the differences between the two main groups in the diagram
labeled 'Different Chemical Forms in the Same Class'?",
      "Question_Type": "Factual"
    },
    {
      "Sl_no": 19,
      "Question": "How can GS-5734 be used to treat acute infections, as well as
chronic ones?",
      "Question_Type": "Explanation"
    },
    {
      "Sl_no": 20,
      "Question": "What do the two diagrams on 'ATP (substrate)' and 'ATP analog
(inhibitor)' represent in the context of the mechanism of action of GS-5734",
      "Question_Type": "Factual"
    }
  ]
}
]

33.[
{
"Sl_no":1,
"Question":"What is the significance of the phrase 'Fostering Value through Innovation'
as the company's slogan?",
"Inference"
},
{
"Sl_no":2,
"Question":"Why do you think the logo 'Cerbios' is placed at the bottom left corner of
the image?",
"Factual"
},
{
"Sl_no":3,
"Question":"In how many countries does CEP have a global presence as mentioned in this
context",
"Factual"
},
{
"Sl_no":4,
"Question":"What are HPAI class 3 and 4 Safebridge ADC payloads, which fall under the
category of small molecules?",
"Explanation"
},
{
"Sl_no":5,
"Question":"Where is Cerbios SA based as mentioned in this context",
"Factual"
},
{
"Sl_no":6,
"Question":"Which international regulatory agency does the US-DMF approval from 1998
imply compliance with?",
"Inference"
},
{
"Sl_no":7,
"Question":"In how many countries does CEP have a presence, according to this context?
Why do they have it in so many countries",
"Factual"
},
{
"Sl_no":8,
"Question":"What is the main focus of Cerbios' development and manufacturing services
for APIs?",
"Factual"
},
{
"Sl_no":9,
"Question":"What does 'cGMP certified by Swissmedic' imply, according to this
context?",
"Factual"
},
{
"Sl_no":10,
"Question":"What is the purpose of a map in the visual representation, according to
this context",
"Inference"
},
{
"Sl_no":11,
"Question":"What are some of the certifications mentioned as company credentials?",
"Summary"
},
{
"Sl_no":12,
"Question":"Who does 'Who We Are' tagline represent for Cerbios? Why is it a suitable
choice as their slogan",
"Inference"
},
{
"Sl_no":13,
"Question":"Which country agency is approved since 2006 in this context, and what does
its approval imply?",
"Factual"
},
{
"Sl_no":14,
"Question":"What do the numbers next to the icons on the world map represent for
Cerbios? Why are they placed there",
"Inference"
},
{
"Sl_no":15,
"Question":"Who is responsible for medicinal products in Switzerland as mentioned in
this context?",
"Factual"
},
{
"Sl_no":16,
"Question":"What does 'Facts and Figures' at the top of the image likely refer to,
according to you?",
"Summary"
},
{
"Sl_no":17,
"Question":"Why do you think a blue arrow is pointing rightward at the bottom left
corner of this image",
"Factual"
},
{
"Sl_no":18,
"Question":"What does 'Known Consignor' mean in this context? What is it related to?",
"Inference"
},
{
"Sl_no":19,
"Question":"In which countries does Cerbios have a presence, according to this context?
In how many years of experience do they have",
"Factual"
},
{
"Sl_no":20,
"Question":"What are the three main groups of therapeutic agents developed by Cerbios
CDMO as mentioned in this context?",
"Inference"
}
]


34.[{"Sl_no":1,"Question":"Who overuses the ED?","Question_Type":"Factual"}]
[{"Sl_no":2,"Question":"What causes ED overuse and what can be done to reduce
it.","Question_Type":"Explanation"}]
[{"Sl_no":3,"Question":"What are some of the strategies to curb ED
overuse?","Question_Type":"Summary"}]
[{"Sl_no":4,"Question":"Who overuses the Emergency
Department?","Question_Type":"Factual"}]
[{"Sl_no":5,"Question":"What causes ED overuse and what can be done to reduce
it?","Question_Type":"Explanation"}]
[{"Sl_no":6,"Question":"What is a matter of urgency- Reducing emergency department
overuse_Overview_03012010:NEHIA Matter of Urgency: Reducing Emergency Department
Overuse\\New England Healthcare Institute\\A NEHI Research Brief - March 2010\\Research
Findings\\The overuse of U.S. emergency departments (EDs) is responsible for $38
billion in wasteful spending each year.","Question_Type":"Factual"}]
[{"Sl_no":7,"Question":"What can be done to reduce the overuse of U.S. emergency
departments (EDs)?","Question_Type":"Application"}]
[{"Sl_no":8,"Question":"Who is responsible for the overuse of the U.S. emergency
departments (EDs)?","Question_Type":"Factual"}]
[{"Sl_no":9,"Question":"What are some strategies to curb ED
overuse?","Question_Type":"Summary"}]
[{"Sl_no":10,"Question":"What are the root causes of ED
overuse?","Question_Type":"Explanation"}]
[{"Sl_no":11,"Question":"What is one of the consequences of ED
overuse?","Question_Type":"Application"}]
[{"Sl_no":12,"Question":"Why is it urgent to reduce emergency department
overuse?","Question_Type":"Factual"}]
[{"Sl_no":13,"Question":"Who are some of the drivers that lead to non-urgent visits in
the emergency care?","Question_Type":"Summary"}]
[{"Sl_no":14,"Question":"What is the estimated annual cost of ED
overuse?","Question_Type":"Factual"}]
[{"Sl_no":15,"Question":"What drives the crisis in primary
care?","Question_Type":"Summary"}]
[{"Sl_no":16,"Question":"Why do some people believe that emergency department use is
solely the result of poor and uninsured flooding EDs for non-urgent health needs;
NEHI's research found that this is far from the truth; these populations are only a
small subset of the overall problem.","Question_Type":"Factual"}]
[{"Sl_no":17,"Question":"What drives the crisis in primary
care?","Question_Type":"Summary"}]
[{"Sl_no":18,"Question":"Who do many patients have little access to timely primary care
services?","Question_Type":"Factual"}]
[{"Sl_no":19,"Question":"How is the emergency department used for non-urgent care and
ED care?","Question_Type":"Summary"}]
[{"Sl_no":20,"Question":"What are some of the consequences of ED
overuse?","Question_Type":"Application"}]


35.[
  {
    "Sl_no": "1",
    "Question": "Which foundation is funding or supporting the TB Drug Accelerator
program?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "2",
    "Question": "What was the primary focus of the presentation this slide came from?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "3",
    "Question": "When does the timeline for the TB Drug Accelerator program begin?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "4",
    "Question": "What was the purpose of the semi-annual meeting scheduled for October
22-23 in this particular year?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "5",
    "Question": "Which disease area has the highest priority according to the
information on this slide?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "6",
    "Question": "What is the name of the organization that funded or supported the TB
Drug Accelerator program in 2013, when the slide was created?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "7",
    "Question": "What are the five new preclinical candidates that must be reached by
the end of 2021, according to this timeline?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "8",
    "Question": "What are the two main areas where funding or support is provided to
researchers through the TB Drug Accelerator program in its early stages? (Note: The
answer may be implied.)",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "9",
    "Question": "In which year will a five-year period for advancing drug candidates
begin and end according to this timeline?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "10",
    "Question": "Who provides support for the NIAID, one of the supporting institutions
mentioned in the slide at the bottom?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "11",
    "Question": "What is the first step in the research process described on this
flowchart?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "12",
    "Question": "Describe how the pharmaceutical companies are involved in the TB Drug
Accelerator program.",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "13",
    "Question": "Why is it important to have a right target, right compound, and right
dose as mentioned at the bottom of this slide?",
    "Question_Type": "Explanation"
  },
  {
    "Sl_no": "14",
    "Question": "What are the four main scopes that make up the flowchart in this
diagram?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "15",
    "Question": "In what order should one go to look for information when trying to
find specific details about the TB Drug Accelerator program?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": "16",
    "Question": "What is the main point of this slide from the title and content?
(Note: The answer may be implied.)",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": "17",
    "Question": "Identify two key groups that have a role to play in the flow of
research, according to this diagram.",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": "18",
    "Question": "Which disease area is expected to achieve more progress with the GHDA'
s focus on the quality and quantity of drug candidates than others?",
    "Question_Type": "Comparison"
  },
  {
    "Sl_no": "19",
    "Question": "How does the TB Drug Accelerator program fit into a larger effort for
global health, as implied by the presence of the Bill & Melinda Gates Foundation
logo?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": "20",
    "Question": "What is the goal for the five-year period that will end in 2021
according to this timeline? (Note: The answer may be implied.)",
    "Question_Type": "Summary"
  }
]


36.
[
  {
    "Sl_no": 1,
    "Question": "What is the title of the presentation that John Rogers presented at
the Connected Healthcare Global Good/Gates Foundation Collaboration meeting?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 2,
    "Question": "Who are Louis Simpson and Kimberly Querry?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 3,
    "Question": "What is the name of the directorship that Louis Simpson holds at
Simpson Querrey Institute",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 4,
    "Question": "What is the name of the professorship held by John A. Rogers at
Simpson Querry Institute?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 5,
    "Question": "Why are conventional hardware for wearables criticized in this
presentation?",
    "Question_Type": "Analytical"
  },
  {
    "Sl_no": 6,
    "Question": "What is the main purpose of having a precision, intimate skin
interface as mentioned in the slide 'Conventional Hardware for Wearables'?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 7,
    "Question": "How do smartwatches and fitness trackers interact with the user's
body?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 8,
    "Question": "What is an example of a measurement that a sweat sensor could
record?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 9,
    "Question": "Who is the author of the paper titled 'Science 333, 838 (2011)'
mentioned in this context?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 10,
    "Question": "What type of data does an epidermal electronics device record?",
    "Question_Type": "Application"
  },
  {
    "Sl_no": 11,
    "Question": "How is the 'Multimodal, Clinical Quality Data' device used in this
context? Where and how does it collect its data?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 12,
    "Question": "What are the three main areas of measurement for clinical standard
that the slides are trying to correlate with using epidermal electronics",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 13,
    "Question": "Who is the author of the presentation titled 'Clinical Standard
Measurements via Skin Interface'?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 14,
    "Question": "What are the three main clinical measurements that are being compared
in this context? What are the devices used for these measurements?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 15,
    "Question": "Which part of the presentation 'Clinical Standard Measurements via
Skin Interface' is shown with photographs and graphs, and what do they represent?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 16,
    "Question": "What are the three main clinical measurements that are being compared
in this context? What are the devices used for these measurements?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 17,
    "Question": "Who is the author of the study titled 'Quantitative Correlation to
Clinical Gold Standards' and how does it compare clinical standard data with
battery-free epidermal data?",
    "Question_Type": "Summary"
  },
  {
    "Sl_no": 18,
    "Question": "How can the ECG waveform in the slide 'Wireless ECG Data, Comparison
to Clinical Standards' be interpreted? What is its importance in this context?",
    "Question_Type": "Analytical"
  },
  {
    "Sl_no": 19,
    "Question": "What are the main areas of measurement for epidermal electronics as
mentioned in this slide 'Measurement Capabilities in Epidermal Electronics'?",
    "Question_Type": "Factual"
  },
  {
    "Sl_no": 20,
    "Question": "How can the graph in the slide be used to compare between clinical and
battery-free ECG data? What does it suggest?",
    "Question_Type": "Analytical"
  }
]


37.[
{
"Sl_no": "1",
"Question": "What is the name of the organization where SWEDD workshop was held?",
"Question_Type": "Factual"
},
{
"Sl_no": "2",
"Question": "Which region is the focus area for the 22 project? Why?",
"Question_Type": "Inference"
},
{
"Sl_no": "3",
"Question": "What are the two objectives of the composite 2 of the 22 project on SWEDD
and the actual SWEDD workshop held on January 18-22, 2016?",
"Question_Type": "Factual"
},
{
"Sl_no": "4",
"Question": "What is the primary goal of the second objective of the 22 project?",
"Question_Type": "Inference"
},
{
"Sl_no": "5",
"Question": "Who are the representatives who presented letters on behalf of their
countries for SWEDD? Why do they need to contribute to SWEDD efforts?",
"Question_Type": "Analytical"
},
{
"Sl_no": "6",
"Question": "What is the name of the document that the SWEDD workshop 2016 aims to
achieve and what are its expected outcomes?",
"Question_Type": "Factual"
},
{
"Sl_no": "7",
"Question": "Why do countries need to prioritize the development of a plan strategic
for SMMN as part of their efforts towards addressing the SMRN challenges? What is the
significance of this effort?",
"Question_Type": "Evaluation"
},
{
"Sl_no": "8",
"Question": "What are the four areas where countries should focus on in order to
address the problems critical to the supply of products for SMN, INF and N? Why are
these the most important ones?",
"Question_Type": "Inference"
},
{
"Sl_no": "9",
"Question": "How can the performance be evaluated and monitored across all the SMMN?
How do you evaluate your own performance?",
"Question_Type": "Factual"
},
{
"Sl_no": "10",
"Question": "What are the ways to ensure that adequate information is provided for data
collection, analysis and processing of information?",
"Question_Type": "Explanation"
},
{
"Sl_no": "11",
"Question": "What are some possible funding mechanisms for SMMN? What does this do to
address the problems critical to the SMN challenges?",
"Question_Type": "Evaluation"
},
{
"Sl_no": "12",
"Question": "How is information adequately provided in the context of data collection,
analysis and processing for SWEDD efforts? Are there any gaps that would hinder its
implementation?",
"Question_Type": "Inference"
},
{
"Sl_no": "13",
"Question": "What are the two types of issues to be addressed when it comes to SMMN
challenges in a region? Why are these two approaches necessary?",
"Question_Type": "Analytical"
},
{
"Sl_no": "14",
"Question": "Why is there a need to have a strategic plan for the SMN supply chain and
what are some of the required resources that would be needed? What do you think will be
the major challenges in implementing this plan?",
"Question_Type": "Factual"
},
{
"Sl_no": "15",
"Question": "What is the expected outcome from the SWEDD regional monitoring framework
for SMN supply chain as a result of the efforts and contributions made by the
countries? What do you think is more important?",
"Question_Type": "Inference"
},
{
"Sl_no": "16",
"Question": "Why are these five areas most important when it comes to addressing SMN
challenges in a region? How would they contribute to improving the regional performance
of SMMN?",
"Question_Type": "Evaluation"
},
{
"Sl_no": "17",
"Question": "What is the role of the four key areas in identifying and prioritizing
problems that are critical to the products supply chain of SMN, INF and N? What should
happen if the four areas are well addressed?",
"Question_Type": "Explanatory"
},
{
"Sl_no": "18",
"Question": "Why would one be surprised about not getting adequate information for data
collection, analysis and processing in SWEDD efforts? Why is this important to address
SMN challenges?",
"Question_Type": "Inference"
},
{
"Sl_no": "19",
"Question": "What are the two categories of problems that need to be addressed when it
comes to the supply chain products for SMN, INF and N? Why are they critical in this
regard?",
"Question_Type": "Factual"
},
{
"Sl_no": "20",
"Question": "How would you rate the availability of quantitative and qualitative data
in a region as important for improving the performance of SMMN compared to other
indicators that one may use to evaluate the performance of the supply chain products?
What is your evidence?",
"Question_Type": "Inference"
}


38.[
{
"Sl_no":1,
"Question":"Why is it important for the Global Health Delivery Strategy team to discuss
the case of paromycinomy in India?",
"Question_Type":"Explanation"
},
{
"Sl_no":2,
"Question":"What is one reason why Paromyciny is not being used as a treatment for
Visceral Leishmaniasis despite being approved by the DCGI in August 2006? Why did this
lead to some management programs including paromycin in their case studies?",
"Question_Type":"Explanation"
},
{
"Sl_no":3,
"Question":"What was the reason why Paromyciny was added to Janani's case study for
Visceral Leishmaniasis treatment guidelines in India? Why did this lead to a delay in
the use of Paromycin as a drug",
"Question_Type":"Explanation"
},
{
"Sl_no":4,
"Question":"What is the current level of fully immunized child coverage in Bihar state
in India?",
"Question_Type":"Factual"
},
{
"Sl_no":5,
"Question":"Who requested that a first-year treatment plan for visceral leishmaniasis
not be included yet in the NWCBD treatment clinic guidelines? What was this for?",
"Question_Type":"Explanation"
},
{
"Sl_no":6,
"Question":"What is the reason why ParomycinCy has been incorporated by some management
programs? What has been the outcome of these requests in India? Why did this happen
after a five-year gap from approval by the DCGI?",
"Question_Type":"Factual"
},
{
"Sl_no":7,
"Question":"Why was Paromyciny chosen as the delivery platform for visceral
Leishmaniasis treatment despite having a high level of Vl disease in Bihar state in
India? What has changed regarding this option recently?",
"Question_Type":"Explanation"
},
{
"Sl_no":8,
"Question":"What is the reason why there is no non-governmental alternative to the
public health system for patients with visceral Leishmaniasis in a country where 80% of
the burden exists?",
"Question_Type":"Factual"
},
{
"Sl_no":9,
"Question":"Why is it difficult to launch new tools being developed for use in India
due to the complexity of the Indian regulatory process and its requirements? What does
this mean for the uptake of Paromyciny",
"Question_Type":"Explanation"
},
{
"Sl_no":10,
"Question":"What are the five major barriers to delivery that were identified by the
Scoping team? What is the name of the technology being discussed in a particular case
study?",
"Question_Type":"Summary"
},
{
"Sl_no":11,
"Question":"What is the main reason why Paromyciny was not adopted as first line
therapy for visceral Leishmaniasis despite being approved by the DCGI and taken five
years to reach this position? What is another drug that has gone through a similar
process in India?",
"Question_Type":"Explanation"
},
{
"Sl_no":12,
"Question":"What are some of the reasons why the foundation has relied on others to
address delivery from PDP grants, to Ministries of Health and the WHO? Is this approach
sufficient to address the magnitude of the problem?",
"Question_Type":"Factual"
},
{
"Sl_no":13,
"Question":"How would the global best practice in the adoption and uptake of new health
technologies be documented by the Global Health Delivery Strategy team? What are some
key steps that could be taken to achieve this goal?",
"Question_Type":"Evaluation"
},
{
"Sl_no":14,
"Question":"What are some management and technology innovations that could further
enhance the effectiveness of delivery platforms? Why is it important for the global
best practice in the adoption and uptake of new health technologies to be documented by
the Global Health Delivery Strategy team?",
"Question_Type":"Explanation"
},
{
"Sl_no":15,
"Question":"How did the Scoping team determine that there were poor regulatory
processes and delays in getting a drug approved? What are the other reasons for the
delay in the use of Paromycin as a first line treatment for Visceral Leishmaniasis?",
"Question_Type":"Summary"
},
{
"Sl_no":16,
"Question":"Why did the foundation's intervention focus on the delivery process rather
than the product development process? How does this focus impact its strategy to
address the suboptimal regulatory and policy processes? What is one way in which the
foundation's strategy could be expanded?",
"Question_Type":"Application"
},
{
"Sl_no":17,
"Question":"How did the establishment of the Delivery team surprise the company? What
are some ways in which the Global Health Delivery Strategy team can contribute to the
efforts to address delivery barriers in other product development activities?",
"Question_Type":"Summary"
},
{
"Sl_no":18,
"Question":"Why would the Scoping team use a case study that shows the poor adoption of
Paromycin as first line treatment for Visceral Leishmaniasis? Why is this important for
the Global Health Delivery Strategy team?",
"Question_Type":"Factual"
},
{
"Sl_no":19,
"Question":"What are some examples of ways in which management and technology
innovations could further enhance the effectiveness of delivery platforms? What can be
one way to encourage reciprocity and evaluation among regulatory agencies in specific
regions?",
"Question_Type":"Application"
},
{
"Sl_no":20,
"Question":"Why is it important for the Global Health Delivery Strategy team to
consider these five sets of barriers to delivery as a whole rather than taking on only
two or three of them? What are some other reasons that there should be a comprehensive
approach in addressing the five delivery gaps?",
"Question_Type":"Summary"
}
]




